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South Africa as a country has a high HIV prevalence. Due to the fact that HIV transmission is 
predominantly heterosexual, HIV discordant couples are a high risk group for HIV. A 
number of HIV prevention interventions have been targeted at HIV discordant couples 
including HIV testing and counselling. An HIV prevention trial assessing the efficacy of 
daily acyclovir on HIV transmission among heterosexual HIV discordant couples was under-
taken in South Africa. We conducted a before and after study with the aim of evaluating the 
effect of HIV counselling and condom provision on sexual behaviour of the heterosexual 
HIV discordant couples enrolled in this prevention trial. Counselling was offered monthly to 
196 HIV-positive index participants and quarterly to their HIV-negative partners. Couple 
counselling was offered to couples quarterly and free condoms provided at every visit. Self 
reported frequency of protected sexual acts in the preceding month was collected using 
interviewer assisted questionnaires at each counselling visit for one year. Urine pregnancy 
tests confirmed pregnancies while clinical examination and laboratory tests were used to 
diagnose genital tract infections. At the end of one year, the incidence rate ratio of protected 
sexual acts among couples was 50% higher than at baseline. Presence of non-primary 
partners among index participants and earning by partner participants reduced the incidence 
rate ratio of protected sex by 25% and 6% respectively. Six percent of the female index 
participants got pregnant during the one year of follow up, with an incident rate of 2.02 per 
10000/year. The prevalence of genital tract infections decreased with time during the study.  
These findings suggest that counselling and provision of condoms to heterosexual HIV 
discordant couples significantly increased the rate of condom use thus reducing the risk of 
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 PART A: PROTOCOL 
EFFECT OF COUNSELLING AND CONDOM PROVISION ON SEXUAL BEHAVIOUR 
OF HETEROSEXUAL HIV DISCORDANT COUPLES AS PART OF AN HIV 
PREVENTION TRIAL SOUTH AFRICA 
1.0 INTRODUCTION  
Sub-Saharan Africa accounted for 67% of the 33 million people globally living with 
HIV/AIDS in 2007 and Southern Africa as a region contributed 35% of this total 
(1)
. The HIV 
epidemic in South Africa is described as hyper-endemic given that more than 15% of the 
adult population (15 to 59 years) are living with HIV 
(1)
. The HIV prevalence in 2008 in the 
Western Cape Province of South Africa was 5.3% in the 15 to 49 year age group 
(2)
. 
Heterosexual transmission between regular couples is an important mode of HIV spread in 
Sub–Saharan Africa 
(1,3)
. HIV discordant couple refers to the situation in which only one 
member of a sexual partnership is HIV infected 
(4)
 and there is evidence of HIV discordance 
in Africa 
(4-10)
. High rates of HIV transmission have been found between HIV discordant 
couples who are often in stable or long term partnerships but unaware of each other’s  HIV 
status 
(6,11)
. These couples may be married or cohabiting. In Sub-Saharan Africa 
approximately 50% of HIV-infected persons are in an HIV discordant relationship 
(12)
 and 
therefore discordance is a major contributor to the spread of HIV. HIV-negative partners 
within HIV discordant relationships are a particularly high risk group for HIV acquisition. 
The focus of prevention strategies among these couples could therefore substantially reduce 
HIV transmission rates.  
A number of strategies have been implemented to prevent the spread of HIV including; 












eligible HIV infected persons with anti-retroviral therapy and counselling on HIV risk 
reduction (abstinence, condom use and monogamy) 
(13,14)
.  
In 2007/2008 a phase III prevention trial was undertaken in 12 sites in Africa to determine if 
suppression of Herpes Simplex II virus using daily acyclovir reduces HIV transmission 
among heterosexual HIV discordant couples. Free condoms and counselling on HIV 
prevention were offered to all study participants during the one year follow up period. We 
sought to evaluate the effect of the counselling and condom provision on the sexual 
behaviour of the HIV discordant couples enrolled at one of the South African trial sites. 
 2.0 PROBLEM 
Many studies on HIV and its prevention are being conducted in Africa due to the high rate of 
HIV transmission in the region. There is a need for measures to prevent HIV transmission in 
such studies using standard practices already known to prevent transmission. For instance, 
counselling on HIV prevention and the provision of condoms are offered as part of all HIV 
prevention trials to encourage participants to practice safer sex. However knowledge on the 
effect of these interventions on sexual behaviour of heterosexual HIV discordant couples is 
limited. Studies among heterosexual HIV discordant couples are limited in South Africa, 
more so those enrolled in prevention trials. 
3.0 JUSTIFICATION 
The existence of unsafe sexual behaviour among HIV discordant couples is well documented 
(7,15)
. In a study of the sexual behaviour of 963 cohabiting heterosexual HIV discordant 
couples less than 3% of couples reported condom use prior to HIV counselling and testing 














All studies using HIV-discordant couples provide counselling and education on ways to 
prevent the spread of HIV, as well as condoms to participants. It is the responsibility of 
researchers to ensure that the risks and benefits of research are balanced in every study. 
Knowledge on the effect of these prevention strategies on sexual behaviour of HIV 
discordant couples is limited and yet relevant to subsequent approaches in HIV prevention 
among these couples and the general population 
(17)
. 
Mathematical models estimated that if a couples’ intervention could reduce HIV transmission 
among HIV discordant couples by 13% every year, 35% to 60% of heterosexually transmitted 
infections would be averted 
(18)
. It is therefore important to determine if HIV prevention 
interventions are effective in reducing transmission risks. 
4.0 RESEARCH QUESTION 
Do counselling and the provision of condoms to heterosexual HIV discordant couples as part 
of an HIV prevention trial lead to less risky sexual behaviour? 
5.0 OBJECTIVES 
5.1 Main objective 
• To identify whether counselling and the provision of condoms as part of an HIV 
prevention trial leads to less risky sexual behaviour of heterosexual HIV discordant 
couples. 
5.2 Subsidiary objectives 
•  To assess condom use amongst heterosexual HIV-discordant couples.  












• To measure the prevalence of genital tract infections among the heterosexual HIV 
discordant couples. 
6.0 LITERATURE REVIEW 
6.1 HIV Discordance in Africa 
HIV discordance refers to a situation in which only one member of a sexual partnership is 
HIV infected 
(4)
. There were regional differences in prevalence of HIV discordance in a 
prevention trial assessing the impact of HSV-2 suppression with acyclovir compared to 
placebo in reducing HIV-1 transmission among HIV discordant couples 
(9)
. Among all 
couples tested in the 12 study sites in Eastern and Southern Africa, HIV discordance ranged 
from 36% to 85% with an overall rate of 49%. In South Africa the prevalence of HIV 
discordance was 27% in 2008 
(9)
. Studies among HIV discordant couples enrolled in 
prevention trials in South Africa are limited. Condom use is an important means of HIV 
prevention among sexually active heterosexual HIV discordant couples 
(19)
. 
6.2 Effectiveness of condom use  
Condom promotion strategies have been widely implemented in Africa to reduce the 
transmission of HIV. A longitudinal study of 343 HIV-negative steady partners of HIV 
infected men indicated that the use of condoms during every sexual encounter was associated 
with a 90% reduction in risk of HIV transmission 
(20)
. In a European multi-country 
prospective study among HIV discordant couples to determine transmission of HIV to 
negative partners, half of the couples reported using condoms at every intercourse and no 
HIV transmission occurred among these couples 
(21)
. In a Haitian HIV discordant couples 
study, among the 177 couples (37%) who remained sexually active after enrolment, the HIV 
seroconversion rate was 5.4 per 100 person year. The infection rate was 1.0 per 100 person 












compared with 6.8 per 100 person years among those who used condoms inconsistently or 
not at all 
(22)
. 
Furthermore, a Cochrane review to estimate condom effectiveness in reducing heterosexual 
transmission of HIV concluded that consistent use of male condoms resulted in an 80% 
reduction in HIV incidence 
(23)
.  Consistency was defined as using a condom for every act of 
penetrative vaginal intercourse.  
6.3 Effects of HIV testing and counselling on sexual behaviour 
Studies have shown that there was an increase in self reported use of condoms by 
heterosexual HIV discordant couples following confidential HIV testing and counselling 
(16,24-27)
. In a prospective study of 60 HIV discordant couples in Kigali, Rwanda, the 
proportion of discordant couples using condoms after HIV testing and counselling increased 




Following voluntary counselling and testing (VCT), at a VCT centre in Lusaka, Zambia, 
more than 80% of reported sexual acts among 963 cohabiting heterosexual discordant couples 




As part of a longitudinal study, husbands and cohabiting partners of 648 Rwandan women 
were recruited in a male-focused HIV counselling programme in Rwanda, Kigali. All women 
and 37% of the men had previously received VCT services. There was increase in self-
reported condom use after one year of follow-up in all couples. A condom ratio (number of 
acts of penetrative sex with condoms as a proportion of the total number of sex acts) was 
used. Regular condom users were couples in whom both partners independently reported 












proportion of couples who qualified as regular condom users increased from 5% to 65% 
among the HIV discordant couples, p< 0.05 
(26)
.  
A systematic review that included a meta-analysis on effects of HIV testing and counselling 
on sexual behaviour was done on studies conducted between 1985 and 1997 
(27)
. This  
review concluded that after HIV testing and counselling, HIV-positive participants and HIV 
discordant couples increased condom use more than HIV-negative and untested participants.  
The weighted mean effect size among the serodiscordant couples was d+= 1.31 (95% CI= 
1.14 – 1.48, Q statistic =147.43, p<0.001) and studies were homogenous. In this study the 
standardised mean difference index (d) was used and positive effect sizes indicated 
reductions in risky sexual behaviour 
(27)
. An effect size of +/-0.2 was considered small, and 




Another systematic review and meta-analysis on effectiveness of behavioural interventions in 
developing countries included studies conducted between 1990 and 2006.  Three of the 
studies measured condom use following HIV counselling and testing among HIV discordant 
couples. Pooled data from these studies (n = 312) showed condom use increased (OR: 67.38; 
95% CI: 36.17–125.52). The Q statistic of 0.96 showed no statistically significant 
heterogeneity p = 0.62; I
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Only one prevention trial on the effectiveness of HIV testing and counselling was identified 
in Africa. Voluntary counselling and testing was associated with a reduction in incidence of 
sexually transmitted infections in this randomised control trial in Kenya 
(29)
. Respondents 
who reported unprotected sexual intercourse with non-primary partners were twice as likely 
to have an incident STI compared to those not reporting unprotected sex with non–primary 












those who did not report this to have an incident STI, p<0.025, after adjusting for unprotected 
sex with non-primary partner at 6 months.  
Studies on the effectiveness of HIV testing and counselling as part of HIV prevention trials 
were limited.  
7.0       METHODOLOGY 
7.1 Study Design  
This will be a before and after study analysing secondary data from an HIV prevention trial. 
Study design of the primary study 
The trial was a randomised, double blind prevention trial. Half of the HIV-positive index 
participants were given acyclovir to suppress genital Herpes and half were given a placebo. 
Information on sexual behaviour was collected prospectively from the cohort of ‘index 
participants’ (HIV-positive) and their partners referred to as ‘partner participants’ (HIV-
negative). This prevention trial was conducted in seven countries, one of which was South 
Africa. There were three sites in South Africa but only data from the Cape Town site will be 
used. Couple counselling and education were offered to all participants during the follow up 
period and condoms provided. Individual counselling was offered if preferred by participants. 
Participants were followed for 12 months in this study. 
7.2 Population and Sampling 
The study was conducted in the Klipfontein sub-district, Cape Town, Western Cape province 
of South Africa. Heterosexual HIV-discordant couples in which the HIV-infected partner had 
a CD4 cell count of at least 250 cells/mm
3













Heterosexual couples were defined as sexual partners of the opposite sex who were married, 
living together, or who otherwise considered the other a primary partner.  In order to be 
considered eligible for this study, both partners had to expect to maintain their relationship 
for at least 24 months.  The index participant could be either a man or a woman.   
The index participant could have had more than one partner who could also have participated 
in the study (e.g. an HIV-infected man with multiple wives or a wife and steady girlfriend). 
The partner participant was allowed to enrol in the study with only one primary partner. 
However, they were not excluded from participating in the study if they had more than one 
sexual partner. 
7.3 Data collection  
Information on sexual behaviour was collected using interviewer-assisted questionnaires. The 
index participants were interviewed on a monthly basis while their partners were interviewed 
quarterly. Couples were asked to report frequency of sexual acts and frequency of those 
sexual acts in which condoms were used. Participants were asked to report on sexual 
behaviour in the preceding month to reduce recall bias. HIV counselling was offered at each 
visit and couples were counselled together quarterly when both partners were scheduled for a 
visit. Both partners underwent not only an HIV risk behaviour interview but also an interview 
to determine if they had symptoms of an STI. Treatment of STIs was based on clinical 
findings and/or laboratory confirmation. The HIV-negative partners underwent HIV testing 
every three months. Condoms were provided at every visit. Pregnancy tests were performed 
on female index participants quarterly and when pregnancy was suspected.  
7.4  Recruitment strategies  
Recruitment strategies included partnering with existing VCT centres and outreach workers, 












community organizations such as churches and community mobilization around the 
importance of couple testing for HIV. Advertisements were placed on bill boards, in 
newspapers and radio talk sessions on the importance of the determination of the HIV status 
of couples. Recruitment materials included education on the probability of being HIV 
discordant; the risk of transmission of HIV and emphasized the benefits of couples VCT with 
specialized counselling services.   
7.5 Inclusion and Exclusion Criteria 
7.5.1  Couples’ inclusion criteria  
• Couples were sexually active (defined as having had vaginal intercourse with the partner 
participant at least three times in the last three months)  
• Couples planned to remain in the relationship for at least 24 months.   
• Both index and partner were at least 18 years of age  
• Both index and partner were able and willing to provide written informed consent to be 
screened for and to take part in the study. 
• Both index and partner were able and willing to provide adequate locator information in 
order to minimise loss to follow up. 
7.5.2  Index participants’ Inclusion criteria 
• HIV-infected based on positive Enzyme Immune Assay.   
• CD4 cell count of at least 250 cells/mm3. 
• No history of any clinical AIDS-defining diagnoses. 
7.5.3  Index participants’ Exclusion Criteria 












• Known history of adverse reaction to acyclovir. 
• Known history of persistent genital ulcers unresponsive to episodic acyclovir therapy. 
• Pregnant, based on participant self-report or urine testing performed by study staff. 
7.5.4 Partner Participants’ Inclusion Criteria  
• HIV-uninfected based on negative HIV EIA tests.  
7.6 Sample size calculation 
Using a sign test of equality of paired proportions with a 5% two-sided level of significance, 
a sample size of 120 pairs will have 86% power to detect a difference in proportions of 0.2 
(20%) when the proportion of discordant pairs is expected to be 0.50. Allowing for 25% non-
response rate, a further 30 pairs would be required giving a sample size of 150 HIV 
discordant couples. 
7.7 Variables   
The main variables that indicated sexual behaviour were; 
• Number of sexual acts with partners during the previous month.  
• Number of sexual acts in which condoms were used in the previous month. 
• Diagnosis of a sexually transmitted infection. 
• Diagnosis of pregnancy based on self report and urinary pregnancy test in female 
participants. 
7.8 Field management 
The trial was conducted in a clinic setting and participants were interviewed, treated and 












All interviews were conducted in isiXhosa.  
7.9 Quality Control 
7.9.1 Improvement of Validity 
Partners in a couple were interviewed separately for privacy and confidentiality in order to 
encourage honest answers. 
Interviewer sex was matched with that of the respondent for respondents to feel at ease while 
giving information. 
7.9.2 Improvement of Reliability 
Reliability was improved by training of interviewers so that questions were asked in the same 
way for all respondents. 
Test re-test method was used in the questionnaire. This method asked the same or connected 
questions in different ways to help interviewer ascertain if similar answers were given by 
respondent.  
7.9.3 Pilot Study 
The study was piloted to ensure respondents understood the questions and to gauge the 
amount of time required for questionnaire administration. 
8.0 DATA MANAGEMENT AND ANALYSIS  
Data will be exported, managed and analysed using STATA version 10.1 
(30)
. Univariate, 












8.1 Sexual behaviour 
We will define protected sexual acts as those acts in which the index participants report 
condom use. Change in sexual behaviour as measured by incidence of protected sexual acts 
reported by index participants at baseline and at follow-up, will be compared using Poisson 
mixed effect models where total number of sexual acts will be the exposure variable. These 
models rely on model-based imputation through maximum likelihoods and thus reduce bias 
from loss to follow-up. The possible predictors of protected sexual acts in addition to time 
(baseline versus follow up), will include demographic and personal characteristics, as well as 
laboratory measurements such as CD4
 
cell count. Several models will be investigated by 
successively adding risk factors to smaller models in a logical stepwise manner. All models 
will be compared with Aikaike’s Information Criterion (AIC) statistics and the final model 
with the lowest AIC will be chosen. Interaction terms will be created between the risk factors 
in the final model if it is believed that effect modification may occur by some variables. They 
will be added to the model one at a time and their significance checked at 5% level. An 
interaction term will be added to the model only if it makes a significant contribution to the 
model, lowers the AIC appreciably and if we have prior knowledge of how it could be 
associated with condom use.  
8.2 Pregnancy 
Pregnancy after enrolment will be an indicator of a sexual encounter without the use of 
condoms. The analysis will be restricted to female index participants of child bearing age (15 
to 49yrs). Descriptive characteristics comparing the women who got pregnant and those who 
did not will be explored. The Kaplan Meier method will be used to analyse and illustrate 
incidence of pregnancy and time to pregnancy. The date of the last menstrual period was 
collected for every pregnant index participant. Survival time for those who became pregnant 












normal menstrual period. Survival time for those who did not become pregnant during the 
one year (censored observations) will be from consent date to their respective last follow up 
date. 
8.3 Genital tract infections  
Prevalence of genital tract infections among female index participants will be summarised by 
calculating the ratio of participants with infection over the total number of participants at 
baseline and at follow up months 3, 6, 9 and 12. Chi-square test for trend will be used to test 
for any trend in prevalence of genital infections with time. 
8.4 Validity of sexual behaviour 
The      total sexual acts and frequency of protected sexual acts by use of condoms reported 
by index participants will be checked against those reported by partner participants for 
validity. Percentage of agreement between index and partner participant responses on these 
variables will be generated using Wilcoxon signed rank test.  
9.0 STUDY LIMITATIONS 
This is a secondary data analysis so its validity is dependent on the validity of the primary 
study. This study will rely on self reported sexual behaviour which is prone to social 
desirability bias yet it was not validated by any other method such as for biological markers 
in the primary study. Recall bias could also bias the sexual behaviour information. 
10.0 ETHICS AND COMMUNICATIONS 
All data for the secondary analysis was provided with no patient identifiers. Confidentiality 
was kept during the trial. Written informed consent was obtained from each study participant 












Participants were compensated for their time and effort and reimbursed for costs associated 
with travel to the study site, time away from work and childcare. Participants were able to 
withdraw from the study at any time if they so wished. 
10.1  Potential Harms 
There will be no potential harm as a result of this secondary analysis of the data. 
10.2  Potential benefits 
The results of this study will be used to inform HIV prevention and policy on counselling of 
heterosexual HIV discordant couples. The study findings will be used as a stepping stone in 
the planning and management of HIV discordant couples who have emerged as a high risk 
group for HIV transmission in Africa. It will add to the body of knowledge around sexual 
behaviour of HIV discordant couples.  
10.3  Results and communication 
The results of this study will be published with permission from the authors of the prevention 
trial with the hope that it will inform policy. All results will be provided to the Department of 
Health, Provincial Government of Western Cape. 
 11.0 LOGISTICS 
11.1 Budget 












11.2 Time line  
  
Year 2010 2011 
Months 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Activity                             
Protocol development                             
Protocol submission 
for approval                             
Literature review                             
Data analysis                             
Results                              
Discussion                             
Write up                             
Journal manuscript                             
 
Months of the year 1 to 12, represent months January to December 2010.  
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PART B: STRUCTURED LITERATURE REVIEW 
1.0 INTRODUCTION 
1.1 Objective 
The objective   of this literature review will be to summarise evidence for the existence of 
HIV discordance in Africa and factors influencing HIV transmission among heterosexual 
HIV discordant couples. Studies on effectiveness of condoms and prevalence of condom use 
among these couples will be highlighted. Predictors of condom use as well as measurement 
of condom use will be discussed further. Lastly a summary of studies on effects of HIV 
testing and counselling on sexual behaviour and validity of sexual behaviour will be 
presented.  
1.2 Search strategy 
Studies on heterosexual HIV discordant couples were identified by searching PubMed, 
Google Scholar, Science Direct and Cochrane library for studies published between 1991 and 
2010. Studies with relevant key words in their titles were identified from reference lists of 
selected studies. Both quantitative and qualitative studies among heterosexual HIV discordant 
couples were selected if they contributed to attaining the goals of the literature review.  
Search terms included; “HIV discordancy”, “HIV discordance”, “HIV discordant couples”, 
“HIV discordant partners”, “HIV transmission discordant couples”, “HIV transmission 
discordant partners”, “condom use” “condom usage”, “effectiveness HIV testing counselling 
sexual behaviour”, “sexual behaviour change VCT”,  “effect VCT sexual behaviour “validity 












1.3  Quality and relevance criteria of included studies 
Studies from both developing countries and developed countries were included in the 
literature review. Most of the articles retrieved were published in peer reviewed journals but 
grey literature from conference proceedings was also included. 
 Systematic reviews of randomised control trials (RCTs), before and after studies as well as 
cohort studies were included for the evidence on effects of HIV testing and counselling on 
sexual behaviour as these had the advantage of synthesizing and summarising most available 
evidence on this topic. Observational studies on factors influencing HIV transmission among 
HIV discordant couples and validity of reported sexual behaviour were included.  
Cross-sectional, cohort, before and after studies, systematic reviews and qualitative studies 
evaluating evidence on prevalence and effectiveness of condom use among heterosexual HIV 
discordant couples were included. Qualitative studies were more appropriate in determining 
perceptions than quantitative studies and hence were included. 
2.0       LITERATURE  
2.1 HIV Discordance in Africa 
HIV discordance refers to a situation in which only one member of a sexual partnership is 
HIV infected 
(1)
. There were regional differences in prevalence of HIV discordance. In 
Eastern and Southern Africa, HIV discordance ranged from 36% to 85% with an overall rate 
of 49% 
(2)
. In South Africa the prevalence of HIV discordance was 27% in 2008 
(2)
. This was 
the only study on HIV discordant couples indentified in South Africa. 
 In a nationally representative HIV/AIDS Sero-Behavioural Survey among adults (15 to 59 
years of age) in Uganda, 40% of cohabiting couples were HIV discordant 
(3)
. An HIV status 












in Uganda, revealed that 52 (43%) of the spouses of the 120 participants on ART, were HIV-
negative. Ninety nine percent of these spouses had never been tested before and were 
therefore unaware of their HIV discordant status 
(4)
.  
Similarly a review of standard demographic and health surveys to describe HIV infection 
among couples in five Eastern and Western African countries (Tanzania, Kenya, Burkina 
Faso, Cameroon and Ghana), revealed that two-thirds of HIV-infected couples were 
discordant and one-third were concordant positive 
(5)
. Women were the infected partner in 30 
to 40% of discordant relationships in these countries. In other studies among HIV discordant 
couples, men were as likely as women to be the HIV infected partner 
(6,7)
.  
 There is an urgent need for interventions targeting HIV discordant couples for HIV 
prevention and a need to assess the effectiveness of these interventions. A critical look at 
factors that influence HIV transmission among heterosexual HIV discordant couples could 
inform HIV prevention strategies among these couples. 
2.2 Factors influencing HIV transmission  
The transmission of HIV infection among adults in sub-Saharan Africa is predominantly 
heterosexual 
(8)
. Studies confirm that a substantial proportion of these heterosexual 
transmissions occur among HIV discordant couples 
(6,9-11)
. For instance in Lusaka, Zambia 
and Kigali, Rwanda, a base model that assumed 20% of HIV discordant relationships result in 
HIV transmission in each 12 month period, estimated that 55% to 93 % of new 
heterosexually acquired HIV infections among adults in urban Zambia and Rwanda occurred 
within HIV discordant marital or cohabiting relationships 
(10)
 .  
A number of factors have been shown to modify the risk of transmission of HIV within 
discordant couples. Persons with advanced clinical stage, low CD4 cell count and high viral 
load were more likely to transmit the virus to their HIV-negative partners 
(12,13)












The higher the frequency of sexual contact within HIV-discordant couples, the higher the 
probability of HIV transmission. The risk of HIV transmission from men to women was 
higher than from women to men 
(6,14,15)
. Besides the sex of the uninfected partner, the more 
sexual partners with whom a person has unprotected sex with, the higher the risk of exposure 
to HIV infection 
(16)
.  
Partner overlap or concurrency increased the risk of HIV transmission 
(17)
. Concurrency 
amplifies transmission because “it exposes multiple partners to the risk of HIV infection and 
thereby creates a potentially large sexual network through which HIV circulates extensively” 
(18)
. Furthermore concurrency increases the risk of spread of other sexually transmitted 
infections among members of a sexual network. 
Genital tract infections including STIs in both HIV-positive and negative individuals are 
associated with increased risks of HIV seroconversion 
(19)
. These infections enhance 
transmission and acquisition of HIV. Genital tract infections increase shedding of the virus in 
the genital tract increasing the probability of transmission from the HIV infected individual. 
Genital tract infection and in particular sexually transmitted infections in the HIV-uninfected 
partner cause ulcers or inflammation which increase susceptibility to HIV 
(20)
.  Ulcerative 




Prevention strategies such as the ABC (abstinence, be faithful, condom use) 
(22)
, antiretroviral 
therapy, VCT and education on transmission risks 
(23-25)
, reduce HIV transmission. Condom 















2.4 Prevalence and effectiveness of condom use  
Condom promotion strategies have been widely implemented in Africa to reduce the 
transmission of HIV. A longitudinal study of 343 HIV-negative steady partners of HIV 
infected men indicated that the use of condoms during every sexual encounter was associated 
with a 90% reduction in risk of HIV transmission 
(27)
. In a European multi-country 
prospective study among HIV discordant couples to determine transmission of HIV to 
negative partners, half of the couples reported using condoms at every intercourse and no 
HIV transmission occurred among these couples 
(28)
. In a Haitian HIV discordant couples 
study, among the 177 couples (37%) who remained sexually active after enrolment, the HIV 
seroconversion rate was 5.4 per 100 person year. The infection rate was 1.0 per 100 person 
years among those who reported that they always used condoms (2.4% of 42 couples), 
compared with 6.8 per 100 person years among those who used condoms inconsistently or 
not at all 
(29)
. 
A Cochrane review to estimate condom effectiveness in reducing heterosexual transmission 
of HIV concluded that consistent use of male condoms resulted in an 80% reduction in HIV 
incidence 
(30)
.  Consistency was defined as using a condom for every act of penetrative 
vaginal intercourse. The reduction in HIV risk with condom use was found to range between 
90% and 95% in another review 
(31)
. 
In a review of prospective studies on effectiveness of condoms in preventing STIs besides 
HIV, it was concluded that condoms protect against these infections 
(32)
. In this review, using 
condoms during more than 25% of sexual acts was associated with a 92% reduction in the 
risk of women acquiring HSV-2 but was not protective among men. Women who reported 
consistent condom use had a 62% reduction in risk of acquiring gonorrhoea and a 26% 












In a qualitative study on knowledge and challenges of HIV prevention amongst discordant 
couples in Uganda, condom use was reported as the preferred prevention strategy for HIV 
transmission.  A number of couples transitioned to condom use after failing to abstain or 
reduce their frequency of sex 
(26)
. 
The prevalence of condom use among HIV discordant couples has been found to be low in 
African studies prior to any intervention 
(23-25)
. In studies enrolling HIV discordant couples, 
condom use prior to HIV testing and counselling was 4% in Kigali, Rwanda 
(23)




A prospective cohort study conducted on the probability of HIV transmission in monogamous 
heterosexual HIV-1 discordant couples in Rakai, Uganda revealed that self reported condom 
use was low in the 174 monogamous couples despite the fact that condoms and counselling 
were promoted and offered free of charge during the study 
(33)
. All the couples were married 
or cohabiting and 161 (92%) had never used condoms, 11 (6%) reported occasional condom 
use and only 2 (1%) reported consistent condom use. 
In a study on HIV serodiscordant couples diagnosed in a referral hospital in Thailand, 
seroconversion occurred in couples who did not consistently use condoms. A higher 
proportion of those who seroconverted reported having sex without condoms (75%) 




An HIV/AIDS Sero-Behavioural Survey among adults in Uganda found that participants who 
knew their HIV status were 3 times more likely to use a condom at last sexual encounter 
compared to untested participants while those who knew their partner’s HIV status were 2.3 
times more likely to use condoms at last sexual encounter compared to those unaware of their 
partner’s status 
(3)












among couples. There were no RCTs on effectiveness of condom use in prevention of STIs 
because this would be un-ethical given the proven effectiveness of condoms. 
2.4.1 Predictors of condom use  
A number of factors were found to be associated with condom use among HIV discordant 
couples. In the California Partners Study of heterosexual HIV discordant couples, 
multivariate analyses showed that inconsistent condom use was associated with injection 
drug use, with younger HIV-positive partner (less than 40 years of age ) (OR= 4.8, 95% CI 
1.0-22.6) but not in couples with an older HIV-positive partner (OR= 0.3, 95% CI 0.1-1.4) 
(35)
. African-American couples reported more inconsistent condom use compared to other 
races (Hispanic, White, Native American, Asian and other). Couples who practiced anal sex, 





count, were more likely to have unprotected sex 
(35)
 . 
In the univariate analysis, inconsistent condom use was associated with; unemployment, 
lower education, injection drug and cocaine use level, practice of anal sex, positive partner 
not receiving ART and higher CD4 cell count of HIV-positive partner in HIV discordant 
heterosexual couples 
(35)
. In this study unemployment was defined as none of the partners 
earning an income while low education (having attained high school graduation or less), drug 
use and practice of anal sex was defined as such if one or both partners had the characteristic. 
A study on HIV transmission among HIV discordant couples in rural Uganda revealed that 
HIV-negative men with infected partners reported more frequent condom use (17%) than 
HIV-positive men with uninfected partners (10%), p< 0.05 
(36)
.  
One of the factors influencing the consistent use of condoms by heterosexual HIV discordant 
















In an exploratory study assessing sexual health, reproductive desires and strategies for 
preventing HIV transmission among HIV discordant couples in long-term relationships in 
South Africa and Tanzania, 51% of couples desired children. The need to avoid infecting the 
HIV-negative partner often conflicted with the desire for children. Sixty percent of 
participants reported that intimacy had been affected by their discordant relationship, with 




In a study to determine the effect of an HIV counselling programme on rates of HIV infection 
and pregnancy in 178 married heterosexual HIV discordant couples in Kinshasa, Democratic 
Republic of Congo, couples seeking to have children minimized their risk of transmission  by 
having unprotected sex only during the woman’s perceived monthly ovulatory period, 
indicating that despite the couples’ desire to have children they understood the risk of 
transmission to the negative partner and limited unprotected sex.  . The overall risk of HIV 
transmission per sexual act was 0.0011 (95% CI 0.0008 – 0.0015) among monogamous 
heterosexual HIV discordant couples in Rakai, Uganda 
(37)
 .  
2.4.2 Condom use measurement 
The measurement of condom use was conducted in various studies on sexual behaviour 
(23,24,29,34)
. It was suggested from reviews that continuous measures of condom use were 
superior to dichotomous measures 
(38)
. Continuous measures encouraged more honest 
answers as they made respondents feel that it was normal and expected by the interviewer 
that they did not use condoms during every previous sexual act 
(39)
. Furthermore continuous 












Recall periods of less than 3 months were more likely to give more accurate results 
(38,40)
. It 
was found that it was important to specify variables related to condom use including partner 
type and type of sex act as these made the resulting data more meaningful 
(40)
. This was 
because there may be differences in rates of condom use between main and casual partners 
and for anal or vaginal sex. Specifying the types of participants and nature of sex allowed 
more meaningful interpretations of studies 
(41)
. 
2.5 Effects of HIV testing and counselling on sexual behaviour 
A number of studies have shown that there was an increase in self reported use of condoms 
by heterosexual HIV discordant couples following confidential HIV testing and counselling 
(23-25,42,43)
. In a prospective study of 60 HIV discordant couples in Kigali, Rwanda, the 
proportion of discordant couples using condoms after HIV testing and counselling increased 




Following voluntary counselling and testing at a VCT centre in Lusaka, Zambia, more than 
80% of reported sexual acts among 963 cohabiting heterosexual discordant couples included 




As part of a longitudinal study, husbands and cohabiting partners of 648 Rwandan women 
were recruited in a male-focused HIV counselling programme in Rwanda, Kigali. All women 
and 37% of the men had previously received VCT services. A condom ratio (number of acts 
of penetrative sex with condoms as a proportion of the total number of sex acts) was used. 
Regular condom users were couples in whom both partners independently reported condom 
use resulting in a condom ratio that exceeded 0.9. The proportion of couples who qualified as 
regular condom users increased from 5% to 65% among the HIV discordant couples at the 














A systematic review that included a meta-analysis on effects of HIV testing and counselling 
on sexual behaviour was done on studies conducted between 1985 and 1997 
(43)
. This  
review concluded that after HIV testing and counselling, HIV-positive participants and HIV 
discordant couples increased condom use more than HIV-negative and untested participants 
 The weighted mean effect size of condom use among the serodiscordant couples was d+= 
 1.31 (95% CI=1.14 – 1.48, Q statistic =147.43, p<0.001) and studies were homogenous. In 
 this study the standardised mean difference index (d) was used and positive effect sizes 
 indicated reductions in risky sexual behaviour 
(43)
. An effect size of +/-0.2 was considered 




Another systematic review and meta-analysis on effectiveness of behavioural interventions in 
developing countries included studies conducted between 1990 and 2006 
(42)
.  Three of the 
studies measured condom use following HIV counselling and testing among HIV discordant 
couples. Pooled data from these studies (n = 312) showed condom use increased (OR: 67.38; 
95% CI: 36.17–125.52). The Q statistic of 0.96 showed no statistically significant 
heterogeneity (p = 0.62; I
2
 = 0.000) across these three studies.  
 
Only one prevention trial on the effectiveness of HIV testing and counselling was identified 
in Africa. Voluntary counselling and testing was associated with a reduction in incidence of 
sexually transmitted infections in this randomised control trial in Kenya 
(45)
. Respondents 
who reported unprotected sexual intercourse with non-primary partners were twice as likely 
to have an incident STI compared to those not reporting unprotected sex with non–primary 
partners, p=0.01. Those who reported unprotected sex at baseline were twice as likely as 
those who did not report this to have an incident STI, p<0.025, after adjusting for unprotected 












Studies on the effectiveness of HIV testing and counselling as part of HIV prevention trials 
were limited. There is a need for further research on whether couple counselling is more 
effective and beneficial compared to individual counselling among heterosexual HIV 
discordant couples, including specially designed counselling strategies to help heterosexual 
HIV discordant couples cope with their serostatus and prevent transmission of the virus to 
their HIV-negative partner and others.  
2.6 Validity of self reported sexual behaviour 
Sexual behaviour is subject to varying degrees of social, cultural, religious, moral and legal 
norms and constraints. Therefore a key challenge of all research using self reported sexual 
behaviour is the generation of unbiased and precise results 
(46)
. 
Validity describes the extent to which an instrument or tool accurately measures what it 
purports to measure. It is extremely difficult to determine the validity of self reported sexual 
behaviour and therefore a number of indirect methods are used. These methods can use 
external or internal validation 
(46)
. 
The internal consistency of questionnaire responses is checked by looking for agreement of 
related questions in the questionnaire and the use of two or more data collection tools to 
collect similar information from the same participants 
(46)
. In a nationally representative 
survey of sexual behaviour in Britain (Natsal study), 19,000 adults aged 16 to 59 years were 
interviewed using face to face interviews and were also asked to complete self-administered 
questionnaires. Answers to particular questions were compared for consistency by the two 
methods. There were 185 consistency checks and 80% of respondents had no inconsistencies. 
However the single most frequent inconsistency was reporting one sexual partner ever in the 














External validation of reports may be achieved by using independent data sources as external 
references 
(46)
 . In the Natsal survey, percentage of self reported therapeutic abortions was 
compared to national reports and was found to be similar. When self reports of having sought 
treatment for past STI symptoms were compared with STI clinic records, there was evidence 
of under-reporting of STI clinic attendance by respondents 
(48)
.  
Interviewing of respondents and their sexual partners separately has been used to test external 
validity 
(49)
. Individual responses differed depending on the stability of the relationship, 
degree of substance abuse and the duration of reporting period 
(50)
. High levels of agreement 
were found in a ten year study on risk factors for HIV transmission among HIV discordant 




Biological methods such as urinary testing for HIV, Chlamydia trachomatis and pregnancy 
were used to assess the validity of self reports on sexual behaviour 
(46)
.  It was hypothesized 
that lower STI incidences would be found in persons who reported consistent condom use 
(52)
.  
There was no difference in incident STIs between STI clinic attendees who reported having 
always used condoms and those who never used condoms at all, suggesting reporting bias. At 
follow up 15.3% of respondents had STIs in both groups.  
When self reported sexual behaviour among HIV discordant couples was validated with 
biological markers there was evidence of under-reporting 
(23)
. Sperm on vaginal swabs, 
pregnancy and linked HIV transmission were used to validate reported protected sex within 
couples. Sperm was present in 25% of vaginal smears taken in intervals with reported 
unprotected sex compared with 15% of smears taken when no unprotected sex was reported 
[P < 0.001]. The detection of sperm in intervals of no reported unprotected sex confirmed 
under-reporting 
(23)












associated with pregnancy while linked HIV transmission was confirmed in 3% of intervals 




In the same study diagnoses of incident episodes of gonorrhoea, syphilis and Trichomonas 
vaginalis were used to validate self report of extra-marital sexual contact. Incidence was 
lower when there were no reported outside sexual contacts by couples compared to when 
outside contacts were reported. The fact that these infections were diagnosed in intervals of 




Heterosexual transmission is an important route of HIV transmission. Given the high rates of 
HIV discordance in South Africa and the region it is important to determine the effects of 
HIV prevention strategies among HIV discordant couples. Studies among HIV discordant 
couples including those determining the effectiveness of VCT among heterosexual HIV 
























(1) de Bruyn G, Bandezi N, Dladla S, Gray G. HIV-discordant couples: An emerging issue in 
prevention and treatment. S Afr Hiv Med. 2009;7(2):25-28.  
(2) Lingappa JR, Lambdin B, Bukusi EA et al. Regional differences in prevalence of HIV-1 
discordance in Africa and enrollment of HIV-1 discordant couples into an HIV-1 prevention 
trial. PLoS One . 2008;3(1(e1411)):1-5.  
(3) Bunnell R, Opio A, Musinguzi J et al. HIV transmission risk behavior among HIV-
infected adults in Uganda: results of a nationally representative survey. AIDS . 
2008;22(5):617-624.  
(4) Were WA, Mermin JH, Wamai N et al. Undiagnosed HIV infection and couple HIV 
discordance among household members of HIV-infected people receiving antiretroviral 
therapy in Uganda. J Acquired Immune Defic Syndromes . 2006;43(1):91-95.  
(5) De Walque D. Discordant Couples: HIV infection among couples in Burkina Faso, 
Cameroon, Ghana, Kenya, and Tanzania. World . 2006:1-28.  
(6) Carpenter LM, Kamali A, Ruberantwari A, Malamba SS, Whitworth JA. Rates of HIV-1 
transmission within marriage in rural Uganda in relation to the HIV sero-status of the 
partners. AIDS . 1999;13(9):1083-1089.  
(7) Eyawo O, de Walque D, Ford N, Gakii G, Lester RT, Mills EJ. HIV status in discordant 
couples in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Infect Dis . 
2010;10:770-777.  
(8) Schmid GP, Buvé A, Mugyenyi P et al. Transmission of HIV-1 infection in sub-Saharan 
Africa and effect of elimination of unsafe injections.  Lancet . 2004;363(9407):482-488.  
(9) Baryarama F, Bunnell R, McFarland W et al. Estimating HIV incidence in voluntary 













(10) Dunkle KL, Stephenson R, Karita E et al. New heterosexually transmitted HIV 
infections in married or cohabiting couples in urban Zambia and Rwanda: an analysis of 
survey and clinical data. Lancet . 2008;371(9631):2183-2191.  
(11) Rispel L, Cloete A, Metcalf C, Moody K. Exploring coping strategies and life choices 
made by HIV-discordant couples in long-term relationships: insights from South Africa, 
Tanzania and the Ukraine: full report. Cape Town: HSRC; 2009.  
(12) Royce RA, Sena A, Cates W,Jr, Cohen MS. Sexual transmission of HIV. N Engl J Med . 
1997;336(15):1072-1078.  
(13) Vernazza PL, Eron JJ, Fiscus SA, Cohen MS. Sexual transmission of HIV: 
infectiousness and prevention. AIDS . 1999;13(2):155-166.  
(14) Hugonnet S, Mosha F, Todd J et al. Incidence of HIV infection in stable sexual 
partnerships: a retrospective cohort study of 1802 couples in Mwanza Region, Tanzania. J 
Acquir Immune Defic Syndr . 2002;30(1):73-80.  
(15) Wiley JA, Herschkorn SJ, Padian NS. Heterogeneity in the probability of HIV 
transmission per sexual contact: the case of male-to-female transmission in penile-vaginal 
intercourse. Stat Med . 2006;8(1):93-102.  
(16) Jewkes R, Dunkle K, Nduna M et al. Factors associated with HIV sero-status in young 
rural South African women: connections between intimate partner violence and HIV. Int J 
Epidemiol . 2006;35(6):1461-1468.  
(17) Shisana O, Rehle T, Simbayi L et al. South African national HIV prevalence, incidence, 
behaviour and communication survey, 2008 : a turning tide among teenagers. Cape Town: 
HSRC; 2009.  
(18) Halperin DT, Epstein H. Concurrent sexual partnerships help to explain Africa's high 












(19) Gray RH, Wawer MJ, Sewankambo NK et al. Relative risks and population attributable 
fraction of incident HIV associated with symptoms of sexually transmitted diseases and 
treatable symptomatic sexually transmitted diseases in Rakai District, Uganda. AIDS . 
1999;13(15):2113-2123.  
(20) Galvin SR, Cohen MS. The role of sexually transmitted diseases in HIV transmission. 
Nature Rev Microbiol . 2004;2(1):33-42.  
(21) Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and 
practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV 
infection. Sex Transm Infect . 1999;75(1):3-17.  
(22) Cohen S. Beyond slogans: Lessons from Uganda's experience with ABC and HIV/AIDS. 
Reprod Health Matters . 2004:132-135.  
(23) Allen S, Meinzen-Derr J, Kautzman M et al. Sexual behavior of HIV discordant couples 
after HIV counseling and testing. AIDS . 2003;17(5):733-740.  
(24) Allen S, Tice J, Van de Perre P et al. Effect of serotesting with counselling on condom 
use and seroconversion among HIV discordant couples in Africa. BMJ. 
1992;304(6842):1605-1609.  
(25) Roth DL, Stewart KE, Clay OJ, van Der Straten A, Karita E, Allen S. Sexual practices of 
HIV discordant and concordant couples in Rwanda: effects of a testing and counselling 
programme for men. Int J STD AIDS . 2001;12(3):181-188.  
(26) Bunnell R, Nassozi J, Marum E et al. Living with discordance: knowledge, challenges, 
and prevention strategies of HIV-discordant couples in Uganda. AIDS Care . 2005;17(8):999-
1012.  
(27) Saracco A, Musicco M, Nicolosi A et al. Man-to-woman sexual transmission of HIV: 
longitudinal study of 343 steady partners of infected men. J Acquired Immune Defic 












(28) De Vincenzi I. A longitudinal study of human immunodeficiency virus transmission by 
heterosexual partners. N Engl J Med . 1994;331(6):341-346.  
(29) Deschamps MM, Pape JW, Hafner A, Johnson WD. Heterosexual transmission of HIV 
in Haiti. Ann Intern Med . 1996;125(4):324-330.  
(30) Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. 
Cochrane Database Syst Rev . 2002;3: CD003255.  
(31) Pinkerton SD, Abramson PR. Effectiveness of condoms in preventing HIV transmission. 
Soc Sci Med . 1997;44(9):1303-1312.  
(32) Holmes KK, Levine R, Weaver M. Effectiveness of condoms in preventing sexually 
transmitted infections. Bull World Health Organ . 2004;82:454-461.  
(33) Gray RH, Wawer MJ, Brookmeyer R et al. Probability of HIV-1 transmission per coital 
act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda.  Lancet . 
2001;357(9263):1149-1153.  
(34) Rojanawiwat A, Ariyoshi K, Pathipvanich P, Tsuchiya N, Auwanit W, Sawanpanylaert 
P. Substantially exposed but HIV-negative individuals are accumulated in HIV-serology-
discordant couples diagnosed in a referral hospital in Thailand. Jpn J Infect Dis . 
2009;62(1):32-36.  
(35) Buchacz K, van der Straten A, Saul J, Shiboski SC, Gomez CA, Padian N. 
Sociodemographic, behavioral, and clinical correlates of inconsistent condom use in HIV-
serodiscordant heterosexual couples.  J Acquired Immune Defic Syndromes . 
2001;28(3):289-297.  
(36) Serwadda D, Gray RH, Wawer MJ et al. The social dynamics of HIV transmission as 












(37) Gray RH, Wawer MJ, Brookmeyer R et al. Probability of HIV-1 transmission per coital 
act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda.  Lancet . 
2001;357(9263):1149-1153.  
(38) Schroder KE, Carey MP, Vanable PA. Methodological challenges in research on sexual 
risk behavior: II. Accuracy of self-reports. Ann  Behav Med . 2003;26(2):104-123.  
(39) Weinhardt LS, Forsyth AD, Carey MP, Jaworski BC, Durant LE. Reliability and validity 
of self-report measures of HIV-related sexual behavior: progress since 1990 and 
recommendations for research and practice. Arch Sex Behav . 1998;27(2):155-180.  
(40) Sheeran P, Abraham C. Measurement of condom use in 72 studies of HIV-preventive 
behaviour: a critical review. Patient Educ Couns . 1994;24(3):199-216.  
(41) Noar SM, Cole C, Carlyle K. Condom use measurement in 56 studies of sexual risk 
behavior: review and recommendations. Arch Sex Behav . 2006;35(3):327-345.  
(42) Kennedy CE, Medley AM, Sweat MD, O’Reilly KR. Behavioural interventions for HIV 
positive prevention in developing countries: a systematic review and meta-analysis. Bull 
World Health Organ . 2010;88(8):615-623.  
(43) Weinhardt LS, Carey MP, Johnson BT, Bickham NL. Effects of HIV counseling and 
testing on sexual risk behavior: a meta-analytic review of published research, 1985-1997. Am 
J Public Health . 1999;89(9):1397-1405.  
(44) Cohen J. Statistical power analysis for the behavioral sciences. New York: Academic 
Press; 1977.  
(45) Coates T, Furlonge C, Mwakagile D, Kamenga C, Schacter J, Gregorich S. Validation of 
self-reported sexual risk behavior with STD incident rates: results from the voluntary HIV 
counseling and testing study . XII International Conference on AIDS. Geneva, June - July 













(46) Fenton KA, Johnson AM, McManus S, Erens B. Measuring sexual behaviour: 
methodological challenges in survey research. Sex Transm Infect . 2001;77(2):84-92.  
(47) Wadsworth J, Field J, Johnson A, Bradshaw S, Wellings K. Methodology of the national 
survey of sexual attitudes and lifestyles. J R Statist Soc . 1993;156(3):407-421.  
(48) Johnson A, Wadsworth J, Wellings K, Field J, Bradsay S. Sexual attitudes and lifestyles, 
British survey. london: Blackwell Scientific; 1994.  
(49) Ostrow DG, Vanable PA, McKirnan DJ, Brown L. Hepatitis and HIV risk among drug-
using men who have sex with men: demonstration of Hart's law of inverse access and 
application to HIV. J  Gay  Lesbian Med Assoc . 2000;3(4):127-136.  
(50) Catania J, Binson D, van der Straten A, Stone V. Methodological research on sexual 
behavior in the AIDS era. Annu Rev Sex Res . 1995;6:77-125.  
(51) Padian NS, Shiboski SC, Glass SO, Vittinghoff E. Heterosexual transmission of human 
immunodeficiency virus (HIV) in northern California: results from a ten-year study. Am J 
Epidemiol . 1997;146(4):350-357.  
(52) Zenilman JM, Weisman CS, Rompalo AM et al. Condom use to prevent incident STDs: 



















PART C: JOURNAL MANUSCRIPT 
AIDS and Behavior journal 
EFFECT OF COUNSELLING EDUCATION AND CONDOM PROVISION ON 
SEXUAL BEHAVIOUR OF HETEROSEXUAL HIV DISCORDANT COUPLES 
Running Head: Effect of counselling on sexual behaviour heterosexual HIV discordant 
couples 
 Dr Phiona Enid Namale
1,4,5
 Dr David Coetzee
 1,2,4,5





Correspondence author: Dr Phiona Enid Namale  
15 Dunvegan Gardens Hope Road Rose Bank 7700 Cape Town Tel: +27 791 966 460  











School of Public Health & Family Medicine
1





 University of Cape Town
4














EFFECT OF COUNSELLING AND CONDOM PROVISION ON SEXUAL BEHAVIOUR OF 
HETEROSEXUAL HIV DISCORDANT COUPLES ENROLLED IN AN HIV PREVENTION 
TRIAL SOUTH AFRICA 
 Phiona Enid Namale. David Coetzee. Francesca Little. 
Abstract 
Studies have been conducted among HIV high risk groups in South Africa to improve HIV 
prevention. A prevention trial to assess efficacy of daily acyclovir on HIV transmission 
among heterosexual HIV discordant couples was conducted in South Africa. HIV counselling 
and condoms were offered to these couples and self reported information on sexual behaviour 
collected. The objective of this study was to examine the effect of counselling and condom 
provision on sexual behaviour of these couples. At the end of one year, the incidence rate 
ratio of protected sexual acts among couples was 50% higher than at baseline. Presence of 
non-primary partners among index participants and earning by the partner participant reduced 
the incidence rate ratio of protected sex by 25% and 6% respectively.  
Counselling and condom provision offered to heterosexual HIV discordant couples as part of 
an HIV prevention trial resulted in an increased rate of condom use. 




















In 2007, Sub-Saharan Africa accounted for 67% of the 33 million people living with 
HIV/AIDS globally and Southern Africa as a region contributed 35% of this total 
(1)
. The 
HIV epidemic in South Africa is described as hyper-endemic given that more than 15% of the 
adult population (15 to 49 years) are living with HIV 
(1)
.  In 2008, the HIV prevalence in 
South Africa was 16.9% (15 to 49 age group) 
(2)
 with an incidence of 17 per 1000 in the 15 to 
20 age group. Thus there is a need for targeted HIV prevention strategies among high risk 
groups, such as; sex workers, men who have sex with men, intravenous drug users and HIV 
discordant couples. 
HIV discordance refers to a situation where only one member of a sexual partnership is HIV 
infected 
(3)
. Despite being in stable or long term partnerships, high rates of HIV transmission 
have been found within heterosexual HIV discordant couples who are often unaware of each 
other’s HIV status 
(4,5)
. In Sub-Saharan Africa approximately 50% of HIV infected persons 
are in an HIV discordant relationship 
(6)
. In South Africa, the prevalence of heterosexual HIV 
discordance was 27% in 2008 
(7)
 and hence they are an important group to target.  
A number of studies have shown that condoms are highly effective in preventing HIV 
transmission 
(8-11)
. Prevalence of condom use among HIV discordant couples was less than 
10% prior to any intervention in African studies 
(12-14)
. 
Only one prevention trial on effectiveness of HIV testing in Africa (Kenya and Tanzania) was 
identified 
(15)
. This prevention trial  showed that HIV counselling and testing was superior to 
provision of health information only, in reducing unprotected sex among both HIV 
concordant and HIV discordant couples  and also decreasing incidences of sexually 
transmitted infections (STIs). Voluntary counselling and testing (VCT) also increased 
condom use among HIV discordant couples in other studies 
(12-14,16,17)












of counselling and condom provision among HIV discordant couples enrolled as part of HIV 
prevention trials in South Africa is limited. 
A number of factors modify the risk of HIV transmission. Later stage of HIV infection, lower 
CD4
 
cell count and high viral loads of the infected partner and STIs in either sexual partner 
increase transmission risk 
(18,19)





 reduce HIV transmission risks.  
In 2007/2008 a phase III placebo controlled prevention trial among heterosexual HIV 
discordant couples was undertaken in 12 sites in Africa to determine if suppression of Herpes 
Simplex II virus using daily acyclovir reduces HIV transmission among heterosexual HIV 
discordant couples. This study assessed the effect of counselling and condom provision on 
sexual behaviour of couples enrolled at one of the South African sites over a one year period. 
METHODS  
Study population 
The prevention trial was conducted in the Klipfontein sub-district, Cape Town, Western Cape 
province of South Africa. Heterosexual HIV-discordant couples in which the HIV-infected 
partner (index participant), had a CD4 cell count of at least 250 cells/mm
3
 at screening and 
their uninfected primary partner (partner participant) were enrolled.  Heterosexual couples 
were defined as sexual partners of the opposite sex who were married, were living together, 
or otherwise considered each other a primary partner.   
Sample size calculation 
Using a sign test of equality of paired proportions with a 5% two-sided level of significance, 
a sample size of 120 pairs had 86% power to detect a difference in proportions of 0.2 (20%) 












response rate, a further 30 pairs were required giving a sample size of 150 HIV discordant 
couples. 
Data collection 
Information on sexual behaviour was collected using interviewer-assisted questionnaires. The 
index participants were interviewed on a monthly basis while their partners were interviewed 
quarterly. Couples were asked to report the total number of sexual acts and frequency of 
condom use in the preceding month. HIV counselling was offered at each visit and couples 
were counselled together quarterly. Individual counselling was offered if preferred by 
participants. Partners underwent HIV testing every three months. Condoms were provided to 
all participants at every visit.  All participants were examined for and asked about symptoms 
of STIs. Treatment of STIs was based on clinical findings and/or laboratory confirmation. 
Urinary pregnancy tests were performed on the female participants quarterly or when 
pregnancy was suspected.  
Data Analysis 




Change in sexual behaviour as measured by incidence of protected sexual acts reported by 
index participants at baseline and at follow-up was compared using Poisson mixed effect 
models where total number of sexual acts was the exposure variable. These Poisson models 
relied on imputation through maximum likelihoods so reduced bias from loss to follow-up. 
Other predictors of protected sexual acts included demographic and personal characteristics, 
as well as laboratory measurements such as CD4 cell count. Several models were investigated 












models were compared with Aikaike’s Information Criterion (AIC) statistics and the final 
model with the lowest AIC was chosen.  
Validity of self reported sexual behaviour  
The frequency of protected sexual acts and total number of sexual acts as reported by index 
participants were checked against those reported by partner participants for validity. 
Percentage of agreement between index and partner participant responses on these variables 
was generated using the Wilcoxon signed rank test.  
Pregnancy 
The analysis was restricted to female index participants of child bearing age (15 to 49 years). 
Descriptive characteristics comparing the women who got pregnant and those who did not 
were explored. The Kaplan Meier method was used to analyse and illustrate incidence of 
pregnancy and time to pregnancy.  
Genital tract infections  
The prevalence of genital tract infections among index participants was summarised by 
calculating the ratio of participants with infection over the total number of participants at 
baseline and at follow up months 3, 6, 9 and 12. Chi-square test for trend was used to show 
the trend in prevalence of genital infections over time. 
RESULTS  
Ninety two (47%) of couples attended all 12 follow-up visits (numbers who attended each 
visit showed in appendix). Index and partner participants lost to follow-up at 12 months were 
not significantly different from those who attended all visits except for age (tables comparing 
characteristics shown in appendix). Table I summarises the baseline characteristics of all 












number earning and percentage of both sexes. Of the 196 index participants enrolled, 79% 
(154) were women and 21% men. The mean age was lower in index participants, 34years (C.I 
32.4−35.02) compared with partner participants, 37years (35.16−37.89), (p<0.001 Paired t-
test). More partner participants than index earned an income, (p= 0.01, Paired t-test). Index 
participants had more years of schooling than partner participants, (p=0.03 Paired t-test). At 
baseline, 6 (3%) of the index participants had other partners while none of the partners 
reported other partners. At follow-up, 7 (4%) of index participants reported having other 

























Table I: Baseline and demographic characteristics of heterosexual HIV discordant 
couples 




Characteristic Mean (Se) Mean (Se) 
Age 33.7 (0.66) 36.5 (0.69) 
Years in school 8.92 (0.19) 8.38 (0.20) 
Characteristic Frequency (%) Frequency (%) 
Females 
Married to study partner 
Living with study partner 
Number earning an income 
Resident in formal settlement 
154 (79) 
  29 (15) 
119 (61) 
  44 (22) 
  98 (50) 
 42 (21) 
 31 (16) 
126 (64) 
  64 (33) 
107 (55) 
 



















Less index participants reported being married to their study partner compared to reports 
from partner participants, 29 compared to 31. Less index participants reported living with 
their study partner compared to partner participants. This is an indication of discrepancy 
among couple responses as same responses would be expected within couples, as each index 
participant was enrolled with one primary partner participant. 
Condom use 
Among all participants regardless of number of visits attended, the mean proportions of 
protected sex at follow up were significantly higher than those at baseline, 0.96 (C.I 
0.92−1.00) and 0.71 (C.I 0.65−0.77) respectively (box and whisker plot shown in appendix). 
Among those who attended all study visits, the mean proportions of protected sex at follow 
up were significantly higher than those at baseline, 0.93 (C.I 0.88−0.97) and 0.63 (C.I 
0.54−0.73) respectively. Table II summarises the associations between protected sexual acts 
and different predictors (model building strategy shown in appendix).  There was a 50% 
increased incidence rate-ratio of protected sexual acts by couples at follow-up compared to 
baseline. If the index participant reported other partners, the incidence rate ratio of protected 
sex among couples reduced by 25%. Earning by partners reduced the incidence rate ratio of 
protected sex among couples by 6%.   This plot of observed against predicted sum of number 






















95% CI Adjusted risk 
ratios 
95% CI 
Time (follow up versus 
baseline) 
1.49 1.38 – 1.62 1.51 1.39 – 1.63 
Presence of other 
partners among index 
participant (yes/no) 




0.94 0.89 – 1.01 0.94 0.89 – 1.00 























Table.III shows the incidence rate ratios in only those who attended all study visits. There 
was a greater increase in incidence risk ratio of protected sex at follow-up compared to 
baseline among couples whose index participant attended all study visits. There was a 74% 
increase in the incidence rate ratio of protected sexual acts among couples who attended all 
visits at follow-up compared to baseline. Comparing models in table II and table III, the 
effect of time was lower in the model for all participants (table II), there was not much 
difference for presence of other partners by index participant but earning by partner is non-
significant in table III. 
Age and sex of participants, earning by index participants, living with study partner, marriage 
to study partner, types of settlement, years of schooling by participants and CD4 cell count of 




























95% CI Adjusted risk 
ratios 
95% CI 
Time (follow up versus 
baseline) 
1.72 1.53 – 1.94 1.74 1.55 – 1.96 
Presence of other 
partners (yes/no) 
0.78 0.62 – 1.00 0.69 0.55 – 0.86 
Partner earning 
(yes/no) 
0.93 0.84 – 1.03 0.92 0.84 – 1.01 






















Validity of self reported condom use 
Index and partner participants gave similar responses more often at baseline compared with 
follow-up with respect to frequency of condom use and total sexual acts. Figure1 and figure 2 
show the percentage agreement among couples. With regards to frequency of condom use 
and total sexual acts, 65% of couples agreed at baseline. This agreement decreased over time 


























Figure1: Percentage agreement of reported condom frequency by couples with time. 
                        






































Figure 2: Percentage agreement of reported sexual frequency by couples with time. 
 





































The median difference in reported condom use at follow up was zero (0) inter-quartile range 
(IQR) (-1 to 1). The median difference in reported sexual acts at follow-up was zero (0) IQR 
(-1 to 2). 
Pregnancy 
There were more female index participants enrolled in the trial 154 (79%).  Four of these 
women were not of reproductive age and were thus excluded from the analysis of time to 
pregnancy. Ten (6%) women got pregnant during the one year of follow up.  
Table IV shows the characteristics of the female index participants of reproductive age and 
those who got pregnant. Those who got pregnant were similar to those who did not in all 
characteristics except for age and type of settlement. The mean age was lower in those who 
got pregnant, 25 years (se =1.88, C.I 22-30) compared with 32 years (se = 4.14 CI 31-34) in 
those who did not. There were 2.02 pregnancies per 10000/year using Kaplan Meier analysis 



















Table IV: Distributions of characteristics among female index participants of 
reproductive age and those who got pregnant 














Married to partner 18 (12%) 3 (17%) 0.10 
Not married to partner 132(88%) 7 (5%)  
Lived with partner 83 (55%) 8 (10%) 0.19 
Did not live with partner 67 (45%) 3 (2%)  
Earned an income 26 (17%) 0 (0%) 0.21 
Did not earn income 124(83%) 10 (8%)  
Informal settlement 73 (49%) 9 (12%) 0.01 
Formal settlement 77 (51%) 1 (1%)  
Had one spouse 146 (97%) 10(100%) 1.00 
Had more than one spouse 4(3%) 0(0%)  
a
 Percentage of the total participants with characteristic 
b
Percentage of participants with characteristic who fell pregnant (row %)
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Genital tract or sexually transmitted infections 
Figure 3 shows the prevalence (in percentage) of genital infections amongst all index 
participants at baseline and figure 4 shows the infections that affect only women. Among 
women, vaginitis was the commonest infection (49%) and the commonest among men was 



























Figure 3: Genital infections among men and women at baseline 
 
Women were diagnosed with a higher percentage of genital infections than men but this was 













































































Figure 5 and figure 6 show the prevalence of infection (in percentage) among index 
participants at follow up. Vaginitis and GUD were still the commonest infection during 
follow-up (number of participants assessed for genital infections at each visit shown in 
appendix). Using the Chi-square test for trend, the prevalence of diagnosis of a genital tract 
infection decreased with time in both women and men (p<0.0001) and (p=0.25) respectively.  
None of the participants were diagnosed with urethitis, gonorrhoea, Chlamydia, bacterial 

























Figure 5: Genital tract infections among men and women at follow up 
 
There were no males diagnosed with syphilis at month 12 and syphilis was diagnosed among 








































Figure 6: Genital tract infections that affect only women at follow up 
 














































This study showed that the heterosexual HIV discordant couples enrolled in this HIV 
prevention trial self reported decreased unprotected sex during the trial. The rate of condom 
use increased over the one year period. This may have been due to the HIV counselling and 
the condoms that these couples received. Condom use was reported to increase among 
couples, who were aware of their partner’s HIV serostatus 
(23)
. 
A similar increase in condom use among HIV discordant couples was reported in other 
studies after VCT for HIV 
(12,16,17,24)
. Unprotected sexual intercourse reduced amongst HIV 
discordant couples in a multicentre randomised control trial in Kenya, Tanzania and Trinidad 
(15)
. In this trial of 6 months duration, couple counselling was compared to provision of health 
information only. Unprotected sex with non-primary partner was shown to increase from 
11% to 15% in the same study (p< 0.05). This reduction in protected sexual acts concurred 
with our findings of a reduction in incidence rate ratio of protected sexual acts if the index 
participant had other partners.  
In South Africa as in most parts of Africa, societies are patriarchal 
(25)
. This social-economic 
difference and power relations may explain why couples in whom partner participants earned 
were less likely to use condoms 
(25)
. The majority of the partner participants were men and 
were more likely to be employed than their female counterparts. This male dominance 
coupled with the fact that women are usually not in a position to negotiate safe sex in 
patriarchal societies 
(26)
 could have led to the reduction in protected sex if partners earned. 
However counselling and condom provision may have encouraged men’s willingness to have 
protected sex at follow-up. 
Contrary to our study results, inconsistent condom use amongst heterosexual HIV discordant 














Unemployment was defined as neither of the partners earning an income and low education 
was defined as one or both partners having attained high school graduation or less. In our 
analysis, we stratified employment by participant. Earning by index participant and education 
level was not significantly associated with condom use. 
The lower effect of time in the model including all participants ( table II ) compared to model 
with only participants who attended all 12 follow-up visits (table III) is probably because 
participants lost to follow-up were less likely to have protected sex. On the other hand, the 
stronger effect of time among those who completed all study visits probably reflects a 
selection bias in that those who attended all visits were more likely to have protected sex. In 
the model with only index participants who completed follow-up, earning by partner was not 
significant probably due to the smaller sample size of 92.  
The low agreement among couple responses shows that estimates of prevalence of protected 
sexual acts were questionable. The medians of reported total sexual acts and protected sexual 
acts was zero and inter-quartile ranges narrow at follow-up so relative comparisons between 
follow up and baseline were better than the low degree of agreement suggests as we relied on 
index participants’ responses at both baseline and follow-up. 
The prevalence of genital tract infections among index participants decreased over the visits 
but this decrease was significant among women only. This reduction may have been due to 
the prompt diagnosis and treatment of infection, counselling on risk reduction and condom 
use to prevent spread of infection and re-infections.  This non-significant reduction of genital 
tract infections among men over visits may be due to the small sample size. There were only 
42 male index participants and any loss to follow up made this number even smaller. The loss 












infections seem higher than it was by reducing the denominator (total number of 
participants).  
Similarly VCT was associated with a reduction in incidence of STIs in a randomised control 
trial in Kenya 
(28)
. In addition many studies have shown evidence of effectiveness of condoms 
in protection against sexually transmitted infections 
(9,11,29)
. The higher prevalence of genital 
infections among women compared with men may be due to physiological and anatomical 
factors such as; large surface area provided by the vagina, presence of vaginal secretions, and 
higher estrogen levels.  
The low rate of pregnancy and decrease in prevalence of genital infections including STIs 
over the one year period supports the findings that rate of condom use increased over time. 
These incident pregnancies and genital tract infections however show lack of or inconsistent 
condom use among some couples. On-going counselling and support could play a vital role in 
maintenance of condom use. 
An assessment of VCT in Kenya and Tanzania showed that it was cost effective 
(30)
.  The cost 
per HIV-1 infection averted was United States dollars (USD) 249 and USD346, in Kenya and 
Tanzania respectively. The cost per DALY saved was USD12.77 in Kenya and USD17.78 in 
Tanzania. In addition 1000 new HIV infections were prevented in the subsequent year in both 
countries 
(30)
. The cost effectiveness of VCT may be improved by integrating couple 
counselling into other HIV prevention strategies and targeting high HIV prevalence areas 
within sub-Saharan Africa where HIV discordant relationships are a high risk group for HIV. 
Studies have shown that VCT is acceptable 
(31-34)
 in Africa and has further research should 
identify the benefits of couples versus individual counselling and the role of support groups 
among HIV discordant couples. No studies have been conducted of the cost effectiveness of 












Our findings suggest that counselling and condom provision play an important role in 
promoting protected sex among HIV discordant couples. However on-going support for these 
couples especially those who are HIV discordant is limited. Our study shows that there would 
be benefit of providing these interventions on an on-going basis. Group based interventions 
among HIV discordant couples may be useful in improving couple communication and 
coping mechanisms on an ongoing basis for these couples. The feasibility of such group 




Couple based HIV prevention interventions have indeed shown positive effects in African 
studies 
(12,36-39)
 such as increasing condom use, disclosure rate, improving adherence to 
antiretroviral treatment and prevention of mother to child  HIV transmission programmes. 
Partner participation is essential in HIV risk reduction strategies 
(40)
 and may improve 
outcomes of these interventions. As evidenced from our findings, characteristics of both 
partners influenced decisions by couples to have protected sex. Presence of other partners by 
index participants and earning by partners reduced the incidence rate ratio of protected sex. 





The strength of this study is the fact that both individual and couple HIV counselling on HIV 
prevention was offered to couples and characteristics of each partner in the heterosexual HIV 
discordant couples was incorporated in our analysis. This allowed us to determine which 
characteristics of either partner played a role in determining safe sex and if this on-going 
counselling for a year influenced sexual behaviour. These results are generalisable to the 
African context where HIV discordant couples are a high HIV risk group and where already 













Implications for research and current practice  
Specially designed individual and couple counselling on prevention of HIV transmission 
among heterosexual HIV discordant couples is a worthwhile prevention strategy 
(41)
 that 
should be incorporated and integrated in other health services such as; family planning 
services, HIV testing and counselling centres, prevention of mother to child HIV transmission 
services and all HIV services. Issues such as; disclosure of HIV status, violence within 
relationships due to discordance and the decision about having children need to be 
incorporated into this counselling. This VCT integration should include monitoring and 
evaluation of outcomes such as condom usage and HIV seroconversion.  
There is a need for further research into which aspects of counselling will be most useful in 
helping heterosexual HIV discordant couples to cope with the discordance, communication 
between couples including prevention of transmission to the negative partner and the general 
population.  
Further research on cost effectiveness and benefits of on-going couple counselling as opposed 
to individual counselling among couples with at least one HIV-positive partner is required. 
Limitations 
The results of this study should be interpreted in light of its methodological limitations. This 
was a secondary data analysis so study validity depended on the primary study. The self 
reported sexual behaviour was not validated by any other method during the primary study 
for example, biological markers. The data on sexual behaviour was self reported and 
therefore prone to recall bias and social desirability. Participants who did not attend all visits 
were less likely to have protected sex so this biased the results towards the null. Therefore the 












this selection bias from loss to follow up. Before and after studies are weak study designs 
compared to experimental studies because they lack randomisation and a comparison group.   
Conclusion 
This before and after study showed that counselling and provision of condoms to 
heterosexual HIV discordant couples as part of an HIV prevention trial  may have contributed 
to increase in the rate of condom use and may therefore play an important role in the 
prevention of HIV. Both partners in an HIV discordant couple need to be involved in any 
HIV prevention strategies. HIV prevention trials involving HIV discordant couples are an 
important avenue for offering and piloting of specially designed counselling to these couples. 
In turn the same counselling can be useful in HIV testing and HIV management centres as a 
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PART D: APPENDICES 
Appendix A: Supplementary results 
Table V: Number of index participants who attended each visit 
Visit 
(Month) 
0 1 2 3 4 5 6 7 8 9 10 11 12 
number 196 184 184 179 181 178 170 176 174 148 142 141 125 
The number of index participants attending each visit reduced with time during the study. 
 




0 1 2 3 4 5 6 7 8 9 10 11 12 
number 180 166 162 157 146 138 133 137 131 112 104 102 86 
The number of index participants who reported at least one sexual act per visit decreased with 


















Figure 7: Protected sex proportions at baseline and follow-up among all participants 
 
0 (baseline)                                                                1(follow-up) 
The proportions of protected sex varied more at baseline than follow-up. During follow up 



































Table VII: Baseline and demographic characteristics of index heterosexual HIV 
discordant couples who completed follow up and those who were loss to follow up 
 Index participants who completed study 
 n=92 
Index participants who did not complete 
study  n=104 
Characteristic Mean (Se) C.I Mean (Se) C.I 
Age 35.88 (0.99) 33.92 –37.84 31.77 (0.86) 30.06 – 33.48 
Years in school 8.76 (0.30) 8.17-  9.35 9.06 (0.24) 8.58 – 9.54 
Characteristic Frequency (%) C.I
a




Married to study 
partner 
Living with study 
partner 
Number earning an 
income 










0.68 – 0.86 
0.07 – 0.23 
 
0.59 – 0.79 
 











0.70 – 0.86 
0.09 – 0.24 
 
0.43 – 0.63 
 
0.18 – 0.35 
 
0.42 – 0.62 
CI (Confidence interval)   % (Percentage)      Se (Standard error)   n (number of participants) 
a
 binomial exact confidence interval 
The index participants who did not complete the study were significantly younger than those 
who completed the study. It appeared as though more of those who completed the study lived 
with their study partner and more of those who did not complete the study earned an income 














Table VIII: Baseline and demographic characteristics of partners of heterosexual HIV 
discordant couples who completed follow up and those who were lost to follow up 
 Partners whose index participants who 
completed study  *n=92 
Partners whose index participants who 
did not complete the study  *n=104 
Characteristic Mean (Se) C.I Mean (Se) C.I 
Age 38.05 (0.99) 33.92 –37.84 35.09 (0.86) 30.06 – 33.48 
Years in school 8.34 (0.32) 7.70-  8.98 8.42 (0.25) 7.92 – 8.92 
Characteristic Frequency (%) C.I
a




Married to study 
partner 
Living with study 
partner 
Number earning an 
income 










0.14 – 0.32 
0.07 – 0.22 
 
0.64 – 0.82 
 
0.24 – 0.44 
 
0.35 – 0.56 
22 (21) 







0.14 – 0.30 
0.11 – 0.27 
 
0.46 – 0.66 
 
0.23 – 0.42 
 
0.48 – 0.67 
CI (Confidence interval)   % (Percentage)      Se (Standard error)   n (number of participants) 
a
 binomial exact confidence interval 
The partners of index participants who completed the study were significantly older than 
partners of index participants who did not complete the study. It appeared as though more 
partners of index participants who completed the study lived with their study partner and 
more of those who did not complete the study lived in formal settlements but these were not 














Table IX: Model selection summary of characteristics associated with use of condoms 
over one year of follow up. 





1 A Time(follow-up versus baseline) 2014.987 < 0.0001        N/A 
2 B Time, presence of other partners 
among index participant  
2007.767 0.0024 Versus 1 
3 V Time, presence of other partners 
among index participant, earning 
by partner participant 
2005.518 0.0393 Versus 2 
4 X Time, presence of other partners 
among index participant, earning 
by partner and earning by index 
participant 
2004.442 0.0795 Versus 3 
5 Z Time, presence of other partners 
among index participant, earning 
by partner, earning by index 
participant, marriage 
2005.916 0.4681 Versus 4 
a
 Likelihood ratio Chi-square test used to generate the p-value 
Aikaike’s Information Criterion (AIC) 
 
The best 1 variable model was model A with the time variable. It had the lowest AIC and was 
significantly better than the null model. 
The best 2 variable model was B. It had the lowest AIC and was significantly better than 












The best 3 variable model was V. It had the lowest AIC and was significantly better than 
model B. Earning by partner participant contributed significantly to model B. 
The best 4 variable model was model X. It had the lowest AIC but was not significantly 
better than model X. Earning by index participant did not contribute significantly to model V. 
 
Figure.8: Kaplan Meir survival estimates of time to pregnancy 
 
The numbers in the bracket are the incident pregnancies at that point in time and the total 
outside the bracket is the number at risk at the same point in time.  
150 (2): means that in the first 60 days, 2 pregnancies occurred among the 150 females who 







150 148(2) 144(3) 143 (0) 137(3) 120(1) 104 (1)  
Number at risk














Table X: Participants who were assessed for genital tract infection over the one year 
period. 





The number of participants assessed for genital tract infections decreased over time 
 
Figure 9: Predicted condom use from model against observed condom use reported by 
index participants 
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The model had a good prediction of number of times condoms were used as showed by how 





































Appendix B: Consent Form Index participants 
Phase III Randomized Placebo-Controlled Trial of HSV-2 Suppression to Prevent HIV 
Transmission among HIV-Discordant Partners 
 ENROLLMENT FOR INDEX PARTICIPANTS 
 
PRINCIPAL INVESTIGATOR:    [insert name] 









We are asking you to volunteer for a research study. This study is for partners in whom one 
person has HIV and the other does not.  HIV is the virus that causes AIDS.  Before you 
decide whether to take part in the study, we would like to explain the purpose of the study, 
the risks and benefits, and what would be expected of you if you agree to be in the study.   
This study is sponsored by the Bill and Melinda Gates Foundation and the University of 












PURPOSE OF THE STUDY 
The research study will find out if a drug called acyclovir can help prevent passing HIV from 
a person who is HIV-infected and has genital herpes to their partner(s) during sex.  Studies 
have shown that having genital herpes infection makes people with HIV more likely to pass 
HIV to others during sex.  Genital herpes is caused by a virus called herpes simplex virus 2 or 
“HSV-2.” Like HIV, HSV-2 is passed from one person to another during sex.  HSV-2 is a 
very common infection with as many as 2 out of 3 people infected in many parts Africa, 
India, and Latin America. Most people who have HSV-2 do not know they have it.  In some 
people, HSV-2 causes sores or itching in the genital area.  Some may not notice any 
symptoms. When HSV-2 is present in the genital area of someone who has HIV, the amount 
of HIV virus in their genital area increases.  This is because the two viruses seem to interact 
in ways that increase the amount and frequency of both viruses in the genital area.  
There is no cure for HSV-2, but an approved drug called acyclovir helps prevent and heal 
genital sores among people who have HSV-2.  Acyclovir is not a treatment for HIV.  But it is 
possible that, by treating HSV-2, acyclovir can help prevent passing HIV from one person to 
another.   
Approximately 3000 couples, mostly from Africa, will be in the study.  This will be the 
largest study of this kind ever, which may help us learn new ways to prevent HIV 
transmission. We will store blood for future studies of HIV, the immune system, and genes 
that may influence whether HIV is transmitted from one person to another. 
 
200-400 couples are planned to be in the study here at [clinic].  We will ask you and your 
partner(s) to be in the study for up to 2 years.  The whole study will take about 4 years to 













YOUR PARTICIPATION IS VOLUNTARY  
This consent form gives information about the study that we will discuss with you.  Once you 
understand the study, and if you agree to take part, we will ask you to sign your name or 
make your mark on this form.  We will offer you a copy to keep. 
Before you learn about the study procedures, it is important that you know the following: 
• You do not have to be in this study if you do not want to join 
• You may decide not to take part in the study, or to withdraw from the study at any time, 
without losing the benefits of your or your partner’s routine medical care 
• If you decide not to take part in the study, you can still join another research study later, if 
one is available and you qualify 
STUDY GROUPS  
If you and your partner are eligible and agree to take part in the study, we will randomly 
place you and your partner in 1 of 2 study groups.  In one group, the partner with HIV will 
get acyclovir pills to take twice a day, every day.  In the other group, the partner with HIV 
will get placebo pills to take twice a day, every day.  The placebo pills look the same as the 












Your group will be chosen “by lot” [or other equivalent local term, for example, like flipping 
a coin or throwing dice]. You have an equal (or “50-50”) chance of being placed in each 
group. You and your partner cannot choose your group.  The study staff also cannot choose 
your group.  Neither you nor the study staff will know which group you are in.  You cannot 
be told which group you are in until about 6-24 months after the end of the study.  This 
means you may have to wait about 1½ to 4 years to find out whether you received acyclovir 
or placebo.   After the study, if the study shows that suppressing herpes is effective in 
reducing the chances of passing HIV to your partner, you will be offered one year of free 
acyclovir as a benefit of being in the study. 
 
Both groups are very important to this study.  Couples in both groups will have the same 
study visits.  All couples will get condoms, treatment for other STDs, and counseling on how 
to avoid HIV and other infections passed during sex.    
 
No matter what study group you are in, you must remember that we do not know if 
acyclovir works to prevent passing HIV from one person to another.  The only known 
way to prevent passing HIV during sex is to use a condom every time you have sex. 
 
STUDY PROCEDURES  
If you decide to take part in the study, your first visit will continue today, after you read, 
discuss, and sign or make your mark on this form.   
 
You will be given a supply of acyclovir or placebo pills and instructions to take one pill twice 












You will receive a genital exam during this visit to look for STDs and to take samples for 
measuring HIV in genital secretions. You will also give blood [up to 57cc/3-4 tablespoons or 
local equivalent] that will be sent to study researchers at the University of Washington.  The 
University of Washington researchers will confirm the results of the HIV and HSV-2 tests 
that we do here. Your blood will be tested for syphilis. 
 
You and your partner will be in the study for up to 24 months (2 years). You will have study 
visits every month, for a total of at least 24 visits.  Your partner will have study visits every 3 
months, for a total of 8 visits.  During the months when you and your partner both have a 
visit, you should come to the clinic together, for your convenience and so you can have 
counselling together as a couple.  If it is not possible to come at the same time, you can come 
for your visits by yourself.  Each visit will take about 60 minutes.   
At each scheduled visit you will: 
• Be asked questions about your health and your sexual practices. 
• Return your bottle of study pills from the past month. 
• Get a new bottle of study pills for the next month. 
• Get condoms. 
• Give urine for a pregnancy test (for women only). 
• Get referrals for medical care and other services if you need them. 
• Be asked for updated information on where you live and how to keep in contact with you.  
The study staff will use this information to remind you of scheduled visits.  If you miss a 
visit, the study staff will try to contact you by [site-specific methods].  They also may 
visit your home to find you.  They will try to reach you through the contact people that 













Every 3 months you also will: 
• Talk with study staff about ways to avoid passing HIV and other infections during sex.  
We encourage you to have this counselling with your partner, but you can have it by 
yourself if you wish. 
• Have a genital exam.  For both men and women, if any sores are seen during the exam, 
the study staff will swab the sore for testing later for HSV at the University of 
Washington.  If the study staff think that the sore is herpes, they may give you acyclovir 
pills to take twice daily for 5 days, in addition to your regular study pills.  If signs of other 
treatable STDs passed during sex are seen during this exam, the study staff will give you 
medicine to treat them as needed.  
• Give blood approximately [21cc/< 2 tablespoons or local equivalent] from your arm that 
will be sent to the University of Washington for tests of the HIV in your blood, your 
immune system, and your genes. 
• Only at the visit that is scheduled to take place three months after joining the study, men 
will be asked but not required to give a semen sample that will be sent to the University 
of Washington for tests of the HIV that may be in the semen.  Men who choose not to 
give this sample may remain in the study.  
Every 6 months you also will:  
• Give some more blood [a total of 57.5ml/3-4 tablespoons or local equivalent] from your 
arm for a CD4 cell count test.  This test gives information on how well your immune 
system is working, and whether you would benefit for treatment to prevent infections 













If your partner becomes HIV infected: 
• During the course of the study we will provide you with condoms and other materials to 
help prevent transmission of HIV to your partner. However it is possible that your partner 
can become HIV infected. If your partner becomes HIV infected, we will continue to 
provide counselling and other support. We will also collect other samples from both you 
and your partner to help us understand HIV transmission from one person to another. We 
will ask you to give blood [21 cc/<2 tablespoons or local equivalent].at these visits: 
- 2-4 weeks after your partner first tests positive for HIV 
- Then 3 months after your partner first tests positive for HIV 
 
At your last visit, you also will: 
• Give some more blood [a total of 57.5ml/3-4 tablespoons or local equivalent] for a 
syphilis test.  The study staff will make arrangements with you to give you the results of 
these test results when they are available.  
At any time in the study:  
• If the study staff suspects that you may be pregnant, you will be asked to give urine for a 
pregnancy test.   
• If you are having health problems that may be due to infections passed during sex, you 
will have a genital exam (as described above). If you have an infection passed during sex 
that is treatable you will receive medicine to treat the infection. 
• You can have extra counselling and testing for HIV if needed between scheduled visits, 
either with your partner or by yourself.   
• If you and your partner end your relationship before your last scheduled study visit, we 












• If you decide to leave the study before your last scheduled study visit, we will ask you to 
have a final study visit with all the exams and tests listed above. 
 
Specimen Storage and use of your samples for future studies:    
We would like to save samples of your blood, urine, semen, and genital secretions at [local 
site] and at the University of Washington for future research by us and by other researchers.  
We will use these samples only for research related to how people get HIV, HSV, HIV-
related diseases and sexually-transmitted infections. This will include testing for genes which 
may affect whether a person is more or less likely to get these infections.  This research is 
experimental and these tests are not useful for your clinical care.  Before your samples leave 
the clinic, they will be assigned a code and your name will not be on them.  Your name will 
be linked to the code only at this clinic and only for five years after the study is completed.  
After that time, the link between your name and the code on your samples will be destroyed.  
An Institutional Review Board or Independent Ethics Committee, which watches over the 
safety and rights of research participants, must approve any future research studies using your 
samples.  If you agree to store your samples, we will keep them for as long as there is sample 
that can be used for future research.  If you do not want to have your samples saved for future 
research, you can still be in this study and your samples will be destroyed once testing for the 
study is completed.  If you agree to store your samples now, but change your mind before the 
end of the study, let the study staff know and we will make sure that your samples do not get 
stored for future research.  We will not sell your samples. Tests done on your samples may 
lead to a new invention or discovery.  We have no plans to share any money or other benefits 














RISKS AND/OR DISCOMFORTS 
Acyclovir is a very safe and effective drug.  It has been used to treat HSV-2 in about 40 
million people.  Side effects are rare. The most common side effects of acyclovir (seen in less 
than 1 of 10 people who take acyclovir) are nausea and headache and, less often, vomiting 
and diarrhoea.  Kidney problems were not reported among more than 70,000 people who took 
acyclovir at the dose used in this study but have been occasionally seen in healthy elderly 
persons or in people with kidney disease who receive a higher dose than will be used in this 
study.  This does not mean that kidney problems will never occur, but that they are very rare. 
Acyclovir is safe to take with other medications, except for probenecid, a medicine that 
sometimes is used to treat gout and syphilis.  If you think that you may be taking probenecid 
at any time during this study, please tell the study staff. 
You may feel discomfort or pain when your blood is drawn.  You may feel dizzy or faint.  
You may have a bruise where the needle goes into your arm.  You may feel discomfort 
during genital exams. 
You may become embarrassed, worried, or anxious when talking about your sexual practices 
and ways to keep from passing HIV, HSV-2, and other infections to your partner.  Talking 
about HIV and HSV-2 and finding out your partner’s test results could cause problems 
between you and your partner.  Trained counsellors will help you and your partner deal with 
any feelings or questions you may have.   
The study staff will make every effort to protect your privacy and confidentiality while you 
are enrolled in the study.  However, it is possible that others may learn that you are in the 
study.  Because of this, they may treat you unfairly or discriminate against you.  For example, 














Acyclovir is not known to cause birth defects. No side effects in newborn babies have been 
reported, but we do not know for sure how safe acyclovir is for unborn babies.  For this 
reason, women who become pregnant while in the study will be asked to stop taking the 
study pills.  
BENEFITS  
You may get no direct benefit from being in this study.  We do not know if acyclovir helps 
prevent passing HIV from one person to another.   Plus, you may not get the acyclovir 
pills.  You may get the placebo pills.  Study staff will remind you of the importance of using 
condoms to prevent passing HIV to your partner. 
 You or others may benefit in the future from information learned in this study. You also may 
get some personal satisfaction from being part of research on HIV. This is true no matter 
what study group you are in. 
You will get counselling and testing for HIV. You will get free condoms.  If you or your 
partner has health problems that may be due to infections passed during sex, you will get 
medicine to treat them, if needed.  If you are in the study group that gets acyclovir, you may 
have fewer genital sores than you otherwise would.  No matter what group you are in, if you 
have a genital sore that is caused by herpes, you may receive acyclovir to treat it. If the study 
shows that acyclovir reduces the chances of passing HIV to HIV uninfected partners, as a 














You will receive care and support related to your HIV infection while this study is ongoing.  
If your CD4 count drops to less than 200, you will be either referred to a clinic where you can 
receive antiretroviral medicines or offered antiretroviral drugs (ARVs) to treat your HIV 
infection.  Depending on when you and your partner join the study, this care will be available 
to you and your partner, if needed, for a maximum of 2 years. This care will be either 
provided through a referral clinic or paid for by the study and will be provided [by the study 
staff or by the xxx organization; EACH SITE INSERT INFO ON WHAT IS AVAILABLE 
HERE].  After the study is over, the study staff will no longer be able to provide this care to 
you or your partner.  You and your partner will be referred to other HIV care programs that 
are available to you (if any). 
For other health problems, the study staff will give you care and treatment that is available at 
the clinic. [EACH SITE INSERT INFO ON WHAT IS AVAILABLE HERE].  For care and 
treatment that is not available at the clinic, study staff will tell you about other places where 
care and treatment may be available. 
 
NEW FINDINGS 
You will be told any new information learned during this study that is important for your 
health or might cause you to change your mind about staying in the study.  You will be told 
when the results of the study may be available, and how to learn about them. 
REASONS WHY YOU MAY BE WITHDRAWN FROM THE STUDY 
You may be removed from the study without your consent for the following reasons: 
• The study staff feels that staying in the study would be harmful to you. 
• The study is stopped or cancelled. 












ALTERNATIVES TO PARTICIPATION 
We do not know if acyclovir works to prevent passing HIV from one person to another 
during sex.  The only known way to prevent passing HIV during sex is to use a condom 
every time you have sex. 
[Sites to include/amend the following if applicable: There may be other studies going on here 
or in the community that you or your partner may be eligible for.  If you wish, we will tell 
you about other studies that we know about.  There also may be other places where you can 
go for HIV counselling and testing.  We will tell you about those places if you wish.] 
COSTS TO YOU   
There is no cost to you for being in this study.  Treatments available to you from the study 
will be given free of charge. 
REIMBURSEMENT 
[Sites to insert information about local incentives:]  
You will receive money [site specified amount] for your time and effort at each scheduled 
study visit.  You also will receive payment for the costs of [lost work, travel, and/or 













Efforts will be made to keep your personal information confidential.  However, absolute 
confidentiality cannot be guaranteed.  Your personal information may be disclosed if required 
by law. Any sample from you or information about you will be identified only by code.  The 
link between your name and code will be kept in a secure location at the clinic only.   We will 
not discuss any information about you with your partner unless you give written permission, 
and will encourage you to be present during the discussion.  Any publication of this study 
will not use your name or identify you personally.    
 
Your study records may be reviewed by study staff and representatives of:  
• the University of Washington, including study monitors 
• the Bill and Melinda Gates Foundation 
• [insert applicable local authorities, e.g., Ministry of Health] 
• [insert names of applicable IRBs/ECs] 
RESEARCH-RELATED INJURY 
The study staff will monitor your health while you are in this study.  You will have a study 
visit every month. If have any health problems between visits — especially nausea, vomiting, 
diarrhea, weight gain, or a decrease in the amount of urine you make — please contact the 














[Sites to amend this sample text as needed, and/or specify institutional policy:]  If you are 
injured as a result of being in the study, the study staff will give you immediate necessary 
treatment for your injuries, free of charge.  The study staff also will tell you where you can 
get additional treatment for your injuries, if needed.  There is no program for monetary 
compensation or other forms of compensation for such injuries.  
PROBLEMS OR QUESTIONS  
If you ever have any questions about this study, or if you have a research-related injury, you 
should contact [insert name of the investigator or other study staff] at [insert telephone 
number and/or physical address]. 
If you have questions about your rights as a research participant, you should contact [insert 
name or title of person on the IRB/EC or other organization appropriate for the site] at [insert 












STATEMENT OF CONSENT AND SIGNATURES   
I have read this form or had it read to me.  I have discussed the information with study staff.  
My questions have been answered. I understand that my decision whether or not to take part 
in the study is voluntary.  I understand that if I decide to join the study I may withdraw at any 
time.  By signing this form I do not give up any rights that I have as a research participant. 
 
[Insert signature blocks as required by the local IRB/EC:]   
 
____________________  ________________________  ______________ 
Participant Name    Participant Signature/Thumbprint   
 Date 
(print) 
____________________ ________________________ ______________ 
Study Staff Conducting Study Staff Signature Date   
Consent Discussion (print) 
 
____________________  ________________________  ______________ 















 Please initial and date one option:  
 
___________        I DO agree to continued follow-up of up to 2 years (24 months) 
 
 __________         I DO NOT agree to continued follow-up of up to 2 years (24 months) 
 
 
____________________  ________________________  ______________ 




SPECIMEN STORAGE AND USE OF YOUR SAMPLES FOR FUTURE STUDIES:  
Please initial and date one option:  
 
___________       I DO agree to store my samples for future research 
 
___________       I DO NOT agree to store my samples for future research 
____________________  ________________________  ______________ 













Appendix C: Consent Form Partner participants 
Phase III Randomized Placebo-Controlled Trial of HSV-2 Suppression to Prevent HIV 
Transmission among HIV-Discordant Couples 
 ENROLLMENT FOR PARTNER PARTICIPANTS 
 
PRINCIPAL INVESTIGATOR:    [insert name] 





We are asking you to volunteer for a research study. This study is for partners in whom one 
person has HIV and the other does not.  HIV is the virus that causes AIDS.  Before you 
decide whether to take part in the study, we would like to explain the purpose of the study, 
the risks and benefits, and what would be expected of you if you agree to be in the study.   
This study is sponsored by the Bill and Melinda Gates Foundation and the University of 
Washington, which are located in Seattle, Washington, USA.   
PURPOSE OF THE STUDY 
The research study will find out if a drug called acyclovir can help prevent passing HIV from 
a person who is HIV-infected and has genital herpes to their partner(s) during sex. Studies 
have shown that having genital herpes infection makes people with HIV more likely to pass 
HIV to others during sex.  Genital herpes is caused by a virus called herpes simplex virus 2 or 












very common infection with as many as 2 out of 3 people infected in many parts Africa, 
India, and Latin America. Most people who have HSV-2 do not know they have it.  In some 
people, HSV-2 causes sores or itching in the genital area.  Some may not notice any 
symptoms. When HSV-2 is present in the genital area of an HIV-infected person, the amount 
of HIV virus in the genital area increases.  This is because the two viruses seem to interact in 
ways that increase the amount and frequency of both viruses in the genital area.  
There is no cure for HSV-2, but an approved drug called acyclovir helps prevent and heal 
genital sores among people who have HSV-2.  Acyclovir is not a treatment for HIV.  But it is 
possible that, by treating HSV-2, acyclovir can help prevent passing HIV from one person to 
another.   
Approximately 3000 couples, mostly from Africa, will be in the study.  This will be the 
largest study of this kind ever, which may help us learn new ways to prevent HIV 
transmission. We will store blood for future studies of HIV, the immune system, and genes 
that may influence whether HIV is transmitted from one person to another. 
200-400 couples are planned to be in the study here at [clinic].  We will ask you and your 
partner(s) to be in the study for up to 2 years.  The whole study will take about 4 years to 
finish.   
 
YOUR PARTICIPATION IS VOLUNTARY  
This consent form gives information about the study that we will discuss with you.  Once you 
understand the study, and if you agree to take part, we will ask you to sign your name or 












Before you learn about the study procedures, it is important that you know the following: 
• You do not have to be in this study if you do not want to join 
• You may decide not to take part in the study, or to withdraw from the study at any time, 
without losing the benefits of your or your partner’s routine medical care 
• If you decide not to take part in the study, you can still join another research study later, if 
one is available and you qualify 
STUDY GROUPS  
If you and your partner are eligible and agree to take part in the study, we will randomly 
place you and your partner in 1 of 2 study groups.  In one group, the partner with HIV will 
get acyclovir pills to take twice a day, every day.  In the other group, the partner with HIV 
will get placebo pills to take twice a day, every day.  The placebo pills look the same as the 
acyclovir pills, but do not contain acyclovir or any other medicine. 
 
Your group will be chosen “by lot” [or other equivalent local term, for example, like flipping 
a coin or throwing dice]. You have an equal (or “50-50”) chance of being placed in each 
group.  You and your partner cannot choose your group.  The study staff also cannot choose 
your group.  Neither you nor the study staff will know which group you are in.  You cannot 
be told which group you are in until about 6-24 months after the end of the study.  This 
means you may have to wait up from about 1 ½ to 4 years to find out.   
Both groups are very important to this study.  Couples in both groups will have the same 
study visits.  All couples will get condoms, treatment for other STDs, and counseling on how 












No matter what study group you are in, you must remember that we do not know if 
acyclovir works to prevent passing HIV from one person to another.  The only known 
way to protect against getting HIV during sex is to use a condom every time you have 
sex. 
STUDY PROCEDURES  
If you decide to take part in the study, your first visit will continue today, after you read, 
discuss, and sign or make your mark on this form.  
You will receive a genital exam to look for STDs. You will give blood [up to 57.5cc/3-4 
tablespoons or local equivalent] today that will be sent to study researchers at the University 
of Washington.   These researchers will confirm the results of the HIV and HSV-2 tests that 
we do here and will look for other genetic, infectious and immune factors that affect the 
chances of becoming HIV-infected. You will be offered counselling about your HSV-2 blood 
test results. Your blood will be tested for syphilis and HSV-2.   
 
You and your partner will be in the study for up to 24 months (2 years).  During the months 
when you and your partner both have a visit, you should come to the clinic together, for your 
convenience and so you can have counselling together as a couple.  If that is not possible, you 

















At each scheduled visit you will: 
• Be asked questions about your health and your sexual practices. 
• Have a genital exam.  If any sores are seen during this exam the study staff will swab the 
sore for later testing for HSV-2 at the University of Washington.  If the study staff think 
that the sore is herpes, they may give you acyclovir pills to take twice daily for 5 days.  If 
signs of other bacterial infections passed during sex are seen during this exam, the study 
staff will give you medicine to treat them as needed. 
• Talk with study staff about ways to avoid HIV and other infections passed during sex.  
We encourage you to have this counselling with your partner, but you can have it by 
yourself if you wish. 
• Talk with study staff about the HIV test and give blood [21 cc/<2 tablespoons or local 
equivalent] from your arm for the test.  When we do HIV testing for this study, we first 
do a test that gives results in about 20 minutes.  You will get the result of that test when it 
is available on the same day you give blood and have the test.  If the test shows that you 
may have HIV infection, we will do another different test to confirm this result.  This test 
takes about 1-2 weeks, so you will have to come back here at that time to get the results. 
You will talk with the study staff about the meaning of your results and how you feel 
about them. Sometimes HIV tests are not clearly positive but also not negative. In that 
case, we will do more tests until we know the result for sure. You must receive your HIV 
test results to stay in the study. 
• Get condoms. 












• Give updated information on where you live and how to keep in contact with you.  The 
study staff will use this information to remind you of scheduled visits.  If you miss a visit, 
the study staff will try to contact you by [site-specific methods].  They also may visit your 
home to find you.  They will try to reach you through the contact people that you list.  If 
they talk to these people, they will not tell them why they are trying to reach you.  
Every 3 months, you also will: 
• Give some more blood [up to 57.5 cc/3-4 tablespoons or local equivalent] for an HIV test 
and to send to study researchers at the University of Washington to look for genetics, 
infectious and immune factors that affect the chances of becoming HIV-infected. 
 
If you become HIV infected: 
• During the course of the study we will provide you with condoms and other materials to 
help prevent transmission of HIV to your partner. However it is possible that you can 
become HIV infected. If you become HIV infected, we will continue to provide 












• If your HIV test result shows that you are infected with HIV, the study staff will talk with 
you about this test result and what this means for you. The staff will obtain a second 
blood test to confirm the initial positive test and you will be referred for care and 
additional counselling and services available to you. If you do become infected with HIV, 
we will ask that you continue your scheduled study visits every 3 months. We will collect 
other samples from both you and your partner to help us understand HIV transmission 
from one person to another. We will ask you to give blood [57.5 cc/3-4 tablespoons or 
local equivalent].at these visits: 
- When you first test positive for HIV 
- 2-4 weeks after you first tests positive for HIV 
- Then every 3 months (quarterly) after your first positive test for HIV. This 
follow-up will continue for a total of 12 months after your first positive test for 
HIV. 
At your last visit, you also will: 
• Give some more blood [up to 57.5 cc/3-4 tablespoons or local equivalent] for tests for 
syphilis.  The study staff will make arrangements with you to give you the results of these 
test results when they are available.  
At any time in the study:  
• If you or the study staff thinks you may be pregnant, you will give urine for a pregnancy 
test (for women only).   
• If you are having health problems that may be due to bacterial infections passed during 
sex, you will have a genital exam (as described above) and receive medicine to treat the 
infections as needed.   
• You can have extra counselling and testing for HIV if needed between scheduled visits, 












• If you and your partner end your relationship before your last scheduled study visit, we 
will ask you to stay in the study as originally scheduled (for 2 years). 
• If you decide to leave the study before your last scheduled study visit, we will ask you to 
have a final study visit with all the exams and tests listed above.  
Specimen Storage and use of your samples for future studies:    
We would like to save samples of your blood, urine, semen, and genital secretions at [local 
site] and at the University of Washington for future research by us and by other researchers.  
We will use these samples only for research related to how people get HIV, HSV, HIV-
related diseases and sexually-transmitted infections.   This will include testing for genes 
which may affect whether a person is more or less likely to get these infections.  This 
research is experimental and these tests are not useful for your clinical care.  Before your 
samples leave the clinic, they will be assigned a code and your name will not be on them.  
Your name will be linked to the code only at this clinic and only for five years after the study 
is completed.  After that time, the link between your name and the code on your samples will 
be destroyed.  An Institutional Review Board or Independent Ethics Committee, which 
watches over the safety and rights of research participants, must approve any future research 
studies using your samples.  If you agree to store your samples, we will keep them for as long 
as there is sample that can be used for future research.  If you do not want to have your 
samples saved for future research, you can still be in this study and your samples will be 
destroyed once testing for this study is completed.  If you agree to store your samples now, 
but change your mind before the end of the study, let the study staff know and we will make 
sure that your samples do not get stored for future research.  We will not sell your samples. 
Tests done on your samples may lead to a new invention or discovery.  We have no plans to 













RISKS AND/OR DISCOMFORTS 
You may feel discomfort or pain when your blood is drawn.  You may feel dizzy or faint.  
You may have a bruise where the needle goes into your arm.  You may feel discomfort 
during genital exams. 
You may become embarrassed, worried, or anxious when talking about your sexual practices, 
ways to protect against HIV and other infections passed during sex, and your HIV and HSV-2 
test results. You may become worried or anxious while waiting for your test results.  If you 
have or become infected with HIV or HSV-2, knowing this could make you worried or 
anxious. Talking about HIV and HSV-2 and finding out your test results could cause 
problems between you and your partner.  Trained counsellors will help you and your partner 
deal with any feelings or questions you may have.   
The study staff will make every effort to protect your privacy and confidentiality while you 
are having the study procedures.  However, it is possible that others may learn of your 
participation here and, because of this, may treat you unfairly or discriminate against you.  
For example, you could have problems getting or keeping a job, or being accepted by your 
family or community. 
BENEFITS  
You may get no direct benefit from being in this study.  We do not know if acyclovir helps 
prevent passing HIV from one person to another.   Plus, your partner may not get the 
acyclovir pills.  He/she may get the placebo pills.  Study staff will remind you of the 












You or others may benefit in the future from information learned in this study. You also may 
get some personal satisfaction from being part of research on HIV. This is true no matter 
what study group you are in. 
You will get counselling and testing for HIV. You will get free condoms.  If you or your 
partner has health problems that may be due to infections passed during sex, you will get 
medicine to treat them, if needed.  If you have a genital sore that is caused by herpes, you 
may receive acyclovir to treat it.  For other health problems, the study staff will give you care 
and treatment that is available at the clinic. [EACH SITE INSERT INFO ON WHAT IS 
AVAILABLE HERE].  For care and treatment that is not available at the clinic, study staff 
will tell you about other places where care and treatment may be available.  
Your partner will receive care and support related to his/her HIV infection while this study is 
ongoing.  Depending on when you and your partner join the study, this care will be available 
to your partner for a maximum of 2 years.  This care will be either be provided through a 
referral clinic or paid for by the study and will be provided [by the study staff or by the xxx 
organization].  Medications used to treat HIV will be given per guidelines of the World 
Health Organization for at least two years.  If you become infected with HIV while in this 
study, you will be offered counselling and clinical services for HIV while the study is 
ongoing.  After the study is over, the study staff will no longer be able to provide this care to 
you or your partner.  You and your partner will be referred to other HIV care programs that 
are available to you (if any). 
NEW FINDINGS 
You will be told any new information learned during this study that is important for your 
health or might cause you to change your mind about staying in the study.  You will be told 












REASONS WHY YOU MAY BE WITHDRAWN FROM THE STUDY 
You may be removed from the study without your consent for the following reasons: 
1. The study is stopped or cancelled. 
2. The study staff feel that staying in the study would be harmful to you. 
3. You are not able to attend study visits or complete the study procedures. 
ALTERNATIVES TO PARTICIPATION 
We do not know if acyclovir works to prevent passing HIV from one person to another 
during sex.  The only known way to protect against HIV during sex is to use a condom 
every time you have sex. 
[Sites to include/amend the following if applicable: There may be other studies going on here 
or in the community that you or your partner may be eligible for.  If you wish, we will tell 
you about other studies that we know about.  There also may be other places where you can 
go for HIV counselling and testing.  We will tell you about those places if you wish.] 
COSTS TO YOU   
There is no cost to you for being in this study.  Treatments available to you from the study 
will be given free of charge. 
REIMBURSEMENT 
[Sites to insert information about local incentives:]  
You will receive money for your transportation costs, time and effort at each scheduled study 
visit.  You also will receive payment for the costs of [lost work, travel, and/or childcare] due 













Efforts will be made to keep your personal information confidential.  However absolute 
confidentiality cannot be guaranteed.  Your personal information may be disclosed if required 
by law.   Any sample from you or information about you will be identified only by code.  The 
link between your name and code will be kept in a secure location at the clinic only.  We will 
not discuss any information about you with your partner unless you give written permission, 
and will encourage you to be present during the discussion.  Any publication of this study 
will not use your name or identify you personally.   
Your study records may be reviewed by study staff and representatives of:  
• the University of Washington, including study monitors 
• the Bill and Melinda Gates Foundation 
• [insert applicable local authorities, e.g., Ministry of Health] 
• [insert names of applicable IRBs/ECs] 
  RESEARCH-RELATED INJURY 
The study staff will monitor your health and the health or your partner while you are in this 
study.  You will have a study visit every 3 months.  Your partner will have a visit every 
month. If you or your partner has any health problems between visits, please contact the 














[Sites to amend this sample text as needed, and/or specify institutional policy:] If you are 
injured as a result of being in the study, the study staff will give you immediate necessary 
treatment for your injuries, free of charge.  The study staff also will tell you where you can 
get additional treatment for your injuries, if needed.  There is no program for monetary 
compensation or other forms of compensation for such injuries.  
PROBLEMS OR QUESTIONS  
If you ever have any questions about this study, or if you have a research-related injury, you 
should contact [insert name of the investigator or other study staff] at [insert telephone 
number and/or physical address]. 
If you have questions about your rights as a research participant, you should contact [insert 
name or title of person on the IRB/EC or other organization appropriate for the site] at [insert 






















STATEMENT OF CONSENT AND SIGNATURES 
I have read this form or had it read to me.  I have discussed the information with study staff.  
My questions have been answered. I understand that my decision whether or not to take part 
in the study is voluntary.  I understand that if I decide to join the study I may withdraw at any 
time.  By signing this form I do not give up any rights that I have as a research participant. 
[Insert signature blocks as required by the local IRB/EC:]   
 
____________________  _________________________  ______________ 
Participant Name    Participant Signature/Thumbprint  Date 
(print) 
____________________ ________________________ ______________ 
Study Staff Conducting Study Staff Signature Date   
Consent Discussion (print) 
____________________  ________________________  ______________ 


















 Please initial and date one option:  
 
___________        I DO agree to continued follow-up of up to 2 years (24 months) 
 
 __________         I DO NOT agree to continued follow-up of up to 2 years (24 months) 
____________________  ________________________  ______________ 
Witness Name    Witness Signature    Date 
(print) 
 
SPECIMEN STORAGE AND USE OF YOUR SAMPLES FOR FUTURE STUDIES:  
Please initial and date one option:  
 
___________       I DO agree to store my samples for future research 
 
___________       I DO NOT agree to store my samples for future research 
 
____________________  ________________________  ______________ 












































































































































































































































Appendix F: Manuscript instructions to authors 
Instructions for Authors 
AIDS and Behavior 
Manuscript Submission 
Seth C. Kalichman, Ph.D.  
Center for HIV Prevention & Intervention  
2006 Hillside Road, Unit 1248  
University of Connecticut  
Storrs, CT 06269  
Email: aidsandbehavior@yahoo.com  
Submission is a representation that the manuscript has not been published previously and is 
not currently under consideration for publication elsewhere. A statement transferring 
copyright from the authors (or their employers, if they hold the copyright) to Springer will be 
required before the manuscript can be accepted for publication. The Editor will supply the 
necessary forms for this transfer. Such a written transfer of copyright, which previously was 
assumed to be implicit in the act of submitting a manuscript, is necessary under the U.S. 
Copyright Law in order for the publisher to carry through the dissemination of research 
results and reviews as widely and effectively as possible.  
AIDS and Behavior now offers the opportunity to publish abstracts for articles in English and 
Spanish. Although not required, I am hoping that you will take advantage of this chance to 
broaden access of your work. If you would like to include your Abstract in Spanish, please be 
sure that your Abstract is in the proper format and finalized. Be sure to remove all 
subheadings from the Abstract so that it reads as a continuous narrative of no more than 150 
words in English. Then translate your final Abstract into Spanish. Upload the English version 
in the Editorial Manager System step for Abstracts and include both the English and Spanish 
versions in your Manuscript file that you upload into the system. The two abstracts should be 
placed together, first the English followed by the Spanish on a separate pages. Label the 












Manuscripts should be submitted to the Editor through Springer’s Editorial Manager Peer 
review system at: http://aibe.edmgr.com 
Manuscript Preparation 
o Type double-spaced on one side of 8 ½ × 11-inch white paper using generous 
margins on all sides, (including copies of all illustrations and tables).  
o A title page is to be provided and should include the title of the article, authors 
name (no degrees), authors affiliation, and suggested running head. The affiliation 
should comprise the department, institution (usually university or company), city, 
and state (or nation) and should be typed as a footnote to the author’s name. The 
suggested running head should be less than 80 characters (including spaces) and 
should comprise the article title or an abbreviated version thereof. For office 
purposes, the title page should include the complete mailing address, telephone 
number, fax number, and email address of the one author designated to review 
proofs.  
o With the exception of Brief Reports and Behavioral Surveillance Reports, initial 
submissions to AIDS and Behavior do not have word or page limits. Briefer and 
more succinct papers tend to review better and papers may be reduced in length as 
part of the review process. However, the length of the original submission is left to 
author discretion. 
o An abstract is to be provided, preferably no longer than 150 words.  
o A list of 4-5 key words is to be provided directly below the abstract. Key words 
should express the precise content of the manuscript, as they are used for indexing 
purposes.  
o All sections should carry headings (such as INTRODUCTION, METHODS, 
RESULTS, DISCUSSION, CONCLUSIONS, etc.), typed flush left. All 
acknowledgments (including those for grant and financial support) should be 
typed in one paragraph (so−headed) on a separate page that directly precedes the 
References section.  
o Illustrations (photographs, drawings, diagrams, and charts) are to be numbered in 
one consecutive series of Arabic numerals. The captions for illustrations should be 
typed on a separate sheet of paper. All illustrations must be complete and final, 












contrast. Drawings should be high quality laser prints or should be prepared with 
india ink. Either the original drawings or good−quality photographic prints are 
acceptable. Artwork for each figure should be provided on a separate sheet of 
paper. Identify figures on the back with authors name and number of the 
illustration. Electronic artwork submitted on disk should be in the TIFF or EPS 
format (1200 dpi for line and 300 dpi for halftones and grayscale art). Color art 
should be in the CYMK color space. Artwork should be on a separate disk from 
the text, and hard copy must accompany the disk.  
o Tables should be numbered (with Roman numerals) and referred to by number in 
the text. Each table should be typed on a separate sheet of paper. Center the title 
above the table, and type explanatory footnotes (indicated by superscript 
lowercase letters) below the table. 
o AIDS and Behavior does not have a limit on number of authors. However, if 
deemed to be excessive the editor may request author justifications and reductions. 
AIDS and Behavior uses Vancouver style as outlined in the American Medical Association 
Manual of style: A Guide for Authors and Editors, 10th Edition.  
A reference number is allocated to a source in the order in which it is cited in the text. In text, 
identify references as Arabic numerals in brackets (1). If the source is referred to again, the 
same number is used. References are listed in numerical order in the Reference List at the end 
of the paper. Do not alphabetize. Use abbreviated names of journals according to the journal 
list in PubMed. List all authors and/or editors up to 6; if more than 6, list the first 3 followed 
by “et al.” The following are examples.  
1) McKirnan DJ, Vanable PA, Ostrow DG, Hope B. Expectancies of sexual "escape" and 
sexual risk among drug and alcohol-involved gay and bisexual men. J Subst Abuse. 
2001;13(1-2):137-54.  
2) van der Straten A, Cheng H, Moore, J et al. The use of the diaphragm instead of condoms 
in a phase III diaphragm trial. AIDS Behav. 2009; 13(3):564-72.  
3) Eaton LA, Kalichman SC. Changes in transmission risk behaviors across stages of HIV 













4) Bangsberg D, Hecht F, Charlebois E, Chesney M, Moss A. Comparing objectives 
measures of adherence to HIV antiretroviral therapy: electronic medication monitors and 
unannounced pill counts. AIDS Behav 2001, 5:275–281.  
5) Richman D, Bozzette S, Morton S, et al. The prevalence of antiretroviral drug resistance in 
the US. Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 2001 
[abstract LB-17].  
6) Hirsch MS, D’Aquila RT, Kaplan JC. Antiretroviral therapy. In: DeVita VT, Hellman S, 
Rosenberg SA, eds. AIDS: Biology, Diagnosis, Treatment and Prevention. 4th ed. 
Philadelphia, PA: Lippincott-Raven; 1997.  
7) Ray SC. Simplot for Windows, version 2.5. Available at: 
http.//www.med.jhu.edu/deptmed/sray/download/. Accessed November 7, 2001.  
Verify that every instance of a number in text corresponds to the numbered reference.  
Footnotes should be avoided. When their use is absolutely necessary, footnotes should be 
numbered consecutively using Arabic numerals and should be typed at the bottom of the page 
to which they refer. Place a line above the footnote, so that it is set off from the text. Use the 
appropriate superscript numeral for citation in the text.  
Page Charge 
The journal makes no page charges. Reprints are available to authors, and order forms with 
the current price schedule are sent with proofs. 
Springer Open Choice 
Springer Open Choice. In addition to the normal publication process (whereby an article is 
submitted to the journal and access to that article is granted to customers who have purchased 
a subscription), Springer now provides an alternative publishing option: Springer Open 
Choice. A Springer Open Choice article receives all the benefits of a regular 
subscription−based article, but in addition is made available publicly through Springer’s 
online platform SpringerLink. To publish via Springer Open Choice, upon acceptance please 
visit the link below to complete the relevant order form and provide the required payment 












regular subscription−model articles. We regret that Springer Open Choice cannot be ordered 
for published articles. 
o www.springer.com/openchoice  
Instructions for Brief Reports 
AIDS and Behavior accepts Brief Reports of soundly designed research studies that are of 
specialized interest or can be considered preliminary findings. An author who submits a Brief 
Report must agree not to submit the full report to another journal. To ensure that a Brief 
Report does not exceed the available journal pages (approximately 4 pages), the text of the 
paper should not exceed 14 pages using one inch margins all around and a font size of 12 
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